WO2021065664A1 - Composition for maintaining or improving daily life activity amount, or for preventing or suppressing decrease in daily life activity amount. - Google Patents
Composition for maintaining or improving daily life activity amount, or for preventing or suppressing decrease in daily life activity amount. Download PDFInfo
- Publication number
- WO2021065664A1 WO2021065664A1 PCT/JP2020/035986 JP2020035986W WO2021065664A1 WO 2021065664 A1 WO2021065664 A1 WO 2021065664A1 JP 2020035986 W JP2020035986 W JP 2020035986W WO 2021065664 A1 WO2021065664 A1 WO 2021065664A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sesamin
- amount
- composition
- activity
- maintaining
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Definitions
- the present invention relates to a composition for maintaining, preventing, suppressing or improving the amount of daily activity.
- the present invention also relates to a method for maintaining, preventing, suppressing or improving the amount of daily activity, and using one or more sesamin for maintaining, preventing, suppressing or improving the amount of daily activity.
- Non-Patent Document 1 discloses that daily activities decrease with aging.
- Non-Patent Document 3 discloses that the higher the amount of physical activity, the longer the healthy life expectancy. In an aging society, it is required to maintain physical activity and extend healthy life expectancy by maintaining not only exercise but also daily activity.
- the amount of human physical activity can be measured using the number of steps as a basic index.
- the measurement of the number of movements by infrared rays and the measurement of the movement distance by telemetry are the mainstream.
- low-intensity activity evaluation is also required to evaluate the amount of daily activity that does not include exercise.
- a measurement method using an activity meter with a built-in triaxial accelerometer has been developed as a method for measuring the amount of daily living activity of humans. Since low-intensity activity can be accurately measured by using this measurement method, it can be an index for more accurately measuring the amount of daily activity. Using this measurement method, it was proved that the amount of daily activity in humans decreases with aging (Non-Patent Document 1).
- Sesamin was subjected to an exercise stress test on rats fed a high-fat diet, and it has been proved in Non-Patent Document 2 that the decrease in endurance is suppressed.
- sesamins prevent a decrease in the amount of daily activity, not exercise, and contribute to the maintenance of the amount of daily activity among physical activities. That is, it was not known that sesamin such as sesamin has an action of maintaining the amount of daily activity. In particular, it has not been reported whether sesamin such as sesamin contributes to the maintenance of activities of daily living with aging.
- An object of the present invention is to provide a composition for maintaining, preventing, suppressing or improving the amount of daily activity. Another object of the present invention is to maintain, prevent a decrease in the amount of daily activity, suppress or improve the decrease, and use one or more sesamin for maintaining, preventing the decrease, suppressing or ameliorating the amount of daily activity. To do.
- Non-Patent Document 1 The present inventors diligently studied to solve the above problems, and measured the activity amount of the rat without applying exercise by using the activity meter with a built-in triaxial accelerometer shown in Non-Patent Document 1. It was found that sesamines have the effect of maintaining the amount of physical activity excluding exercise, that is, the amount of living activity. In addition, the present inventors have found that sesamin are useful for preventing or maintaining a decrease in the amount of daily activity that decreases with age.
- the present invention relates to the following compositions for maintaining, preventing, suppressing or improving the amount of daily activities.
- a composition for maintaining, preventing, suppressing or improving the amount of daily activity containing one or more of sesamin.
- Prevention or suppression of decrease in daily activity due to aging, improvement of decrease in daily activity with aging, prevention or suppression of increase in inactivity time with aging, increase in inactivity time with aging The composition according to any one of the above [1] to [3] for improving the above.
- oral composition is a food or drink, a pharmaceutical product, a quasi drug, or a feed.
- food or drink is a food for specified health use, a nutritionally functional food, or a food with functional claims.
- the present invention it is possible to provide a composition for maintaining, preventing, suppressing or improving the amount of daily activity. Further, according to the present invention, it is possible to provide a method for maintaining, preventing, suppressing or improving the amount of daily activity. Further, according to the present invention, it is possible to provide the use of one or more kinds of sesamin for maintaining, preventing, suppressing or improving the amount of daily activity. Ingestion of one or more of sesamin has the effect of maintaining, preventing, suppressing or improving the amount of daily activity. Ingestion of one or more sesamin species prevents or suppresses the decrease in daily activity due to aging, improves the decrease in daily activity due to aging, or prevents the increase in inactivity time due to aging. , Can be suppressed or improved.
- the sesamin used in the present invention is a component that has been ingested as a food for a long time, and is also advantageous in that it is highly safe and can be continuously ingested.
- the composition for maintaining, preventing, suppressing or improving the amount of daily activity of the present invention contains one or more sesamin.
- Sesamin is one of the main lignan compounds of sesame, and is contained in sesame in an amount of about 0.5 to 1.0% by weight. While long-term ingestion of artificially synthesized compounds is not preferable from the viewpoint of unexpected side effects and the like, sesamins whose safety is guaranteed are most suitable for long-term ingestion.
- physical activity, exercise, and living activity have the same meaning as the definitions of physical activity, exercise, and living activity in the "Exercise Guideline for Health Promotion 2006" issued by the Ministry of Health, Labor and Welfare. .. That is, physical activity is all activities that consume more energy than in a resting state, and living activities are physical activities other than exercise.
- the exercise is carried out systematically and intentionally for the purpose of maintaining and improving physical fitness, for example.
- the amount of daily activity can be measured using an activity meter with a built-in triaxial accelerometer (Actimarker manufactured by Panasonic Corporation). Animals can be measured using an activity meter with a built-in triaxial accelerometer (nanotag manufactured by Kissei Comtech Co., Ltd.) under conditions such as a treadmill that do not impose exercise.
- the life activity in the present invention is not particularly limited, and examples thereof include household chores, work and / or childcare activities in humans. In animals, the amount of activity measured under the condition that no exercise is applied is considered to correspond to the amount of daily activity in humans.
- the amount of daily activity can be measured as the amount of daily activity and / or the time of daily activity. That is, maintenance, prevention of decrease, suppression or improvement of decrease in the amount of daily activity means maintenance, prevention of decrease, suppression or improvement of decrease in amount of daily activity and / or living activity time. Since the inactivity time increases due to the decrease (decrease) in the living activity time, the prevention, suppression or improvement of the increase in the inactivity time is also used for maintaining, preventing the decrease, suppressing or improving the amount of living activity in the present invention. included.
- the inactivity time means a time during which physical activity is not performed, that is, a time during rest such as sleeping or sitting behavior.
- the above-mentioned maintenance, prevention of decrease, suppression or improvement of decrease in daily activity means prevention or suppression of decrease in daily activity, improvement of decreased daily activity, prevention or suppression of increase in inactivity time, or increased inactivity time. It is preferable that it is an improvement.
- the maintenance, prevention of decrease, suppression or improvement of the above-mentioned amount of daily activity is the prevention or suppression of the decrease in the amount of daily activity associated with aging, the improvement of the amount of daily activity decreased with aging, and the inactivity time associated with aging. It is preferable to prevent or suppress the increase and improve the inactivity time that has increased with aging.
- aging refers to a change associated with an increase in age after middle and old age, especially after about 40 years old.
- sesamin is a general term for compounds containing sesamin and its analogs. Sesamin is one of the major lignan compounds contained in sesame seeds. Examples of sesamin analogs include episesamin and dioxabicyclo [3.3.0] octane derivatives described in JP-A-4-9331. As one or more kinds of sesamin, one kind of compound may be used alone, or two or more kinds may be used. Specific examples of sesamin include sesamin, episesamine, sesaminol, episesaminol, sesamol, sesamolin and the like, and these stereoisomers or racemates can be used alone or in combination.
- sesamin and / or episesamin can be preferably used as one or more of the sesamin, sesamin and episesamin, or episesamin can be more preferably used, and episesamin can be further preferably used. ..
- sesamin and episesamin are used, their ratios are not particularly limited, but for example, sesamin: episesamin (weight ratio) is preferably 1: 0.1 to 1: 9, and more preferably 1: 0.3 to 1: 3. , 1: 0.5 to 1: 2 is more preferable.
- sesamin used in the present invention is not limited by its form, production method, or the like.
- sesamin referred to as sesamin extract or purified product
- a known method for example, the method described in JP-A-4-9331
- commercially available sesame oil (liquid) can be used as it is.
- sesame oil liquid
- the flavor peculiar to sesame oil may be evaluated as sensually unfavorable. Therefore, a tasteless and odorless sesamin extract (or refined sesamin product) extracted from sesame oil is used. Is preferable.
- sesame oil when sesame oil is used, the sesamin content is low, and if a preferable amount of sesamin is to be added, the volume of the prescribed composition per unit dose becomes too large, which may cause inconvenience in intake. ..
- the formulation tablettes, etc.
- one or more of purified or isolated sesamin may be used. Sesamin can also be obtained by synthesis.
- sesamin and episesamin can be synthesized by the method of Beroza et al. (J. Am. Chem. Soc., 78, 1242 (1956)).
- the metabolites of sesamin and episesamin can be synthesized by the method of Urata et al. (Chem. Pharm. Bull. (Tokyo), 56 (11) 1611-2 (2008)).
- Sesamin is a compound that is contained in natural products and foods and drinks and has eating experience. Therefore, from the viewpoint of safety, sesamin is considered to have few problems in ingestion every day, for example. According to the present invention, it is possible to provide a composition for maintaining, preventing, suppressing or improving the amount of daily activity containing a highly safe substance as an active ingredient.
- the composition of the present invention can be applied to either therapeutic use (medical use) or non-therapeutic use (non-medical use).
- Non-therapeutic is a concept that does not include medical practice, ie human surgery, treatment or diagnosis.
- the composition of the present invention can be in the form of food and drink, pharmaceuticals, quasi-drugs, feed and the like.
- the composition of the present invention may itself be a food or drink, a drug, a quasi-drug, a feed, etc. for maintaining, preventing, suppressing or improving the amount of daily activity, and is used in combination with these. It may be a material or a preparation to be used.
- the composition of the present invention can be provided, for example, in the form of an agent, but is not limited to this form.
- the agent can be provided as it is as a composition or as a composition containing the agent.
- the composition of the present invention may be either an oral composition or a parenteral composition, but is preferably an oral composition.
- examples of the oral composition include foods and drinks, oral medicines, quasi-drugs, and feeds, preferably foods and drinks or oral medicines, and more preferably foods and drinks.
- composition of the present invention may contain any additive and any component in addition to one or more sesamins as long as the effects of the present invention are not impaired.
- additives and ingredients can be selected according to the form of the composition and the like, and generally those that can be used for foods and drinks, pharmaceuticals, quasi-drugs, feeds and the like can be used.
- the composition of the present invention is a food or drink, a pharmaceutical product, a quasi-drug, a feed or the like
- the production method thereof is not particularly limited and can be produced by a general method.
- composition of the present invention when used as a food or drink, one or more kinds of sesamin are mixed with ingredients that can be used in the food or drink (for example, food materials, food additives used as needed, etc.).
- Various foods and drinks can be used.
- Foods and drinks are not particularly limited, and examples thereof include general foods and drinks, health foods, dietary supplements, health drinks, foods with functional claims, foods for specified health use, foods and drinks for the sick, and the like.
- the above-mentioned health foods, health supplements, foods with functional claims, foods for specified health use, etc. include, for example, fine granules, tablets, granules, powders, capsules, chewables, dry syrups, syrups, liquids, beverages, fluids. It can be used as various formulations such as food.
- composition of the present invention is a pharmaceutical product or a quasi-drug
- a pharmacologically acceptable carrier for example, an additive added as necessary, or the like is blended with one or more of sesamin. It can be a drug of various dosage forms or a quasi-drug.
- Such carriers, additives and the like may be pharmacologically acceptable as long as they can be used in pharmaceutical products or quasi-drugs, and for example, excipients, binders, disintegrants, lubricants, etc.
- antioxidants, colorants and the like can be mentioned.
- Examples of the administration (ingestion) form of the drug or quasi-drug include oral or parenteral (transdermal, transmucosal, intestinal, injection, etc.) administration forms.
- composition of the present invention is a drug or a quasi-drug
- it is preferably an oral drug or a quasi-drug.
- Dosage forms for oral administration include liquids, tablets, powders, fine granules, granules, sugar-coated tablets, capsules, suspensions, emulsions, chewables and the like.
- the drug may be a non-human veterinary drug.
- composition of the present invention When the composition of the present invention is used as a feed, one or more of sesamin may be added to the feed.
- the feed also contains feed additives. Examples of the feed include livestock feed used for cattle, pigs, chickens, sheep, horses and the like; small animal feed used for rabbits, rats, mice and the like; pet food used for dogs, cats, small birds and the like.
- the content of sesamin contained in the composition of the present invention is not particularly limited and can be set according to the form and the like.
- the total content of sesamin in the composition of the present invention is, for example, preferably 0.001% by weight or more, more preferably 0.01% by weight or more, still more preferably 0.05% by weight or more in the composition. , 10% by weight or less is preferable, and 5% by weight or less is more preferable.
- the total content of sesamin is preferably 0.001 to 10% by weight, more preferably 0.01 to 5% by weight, still more preferably 0.05 to 5% by weight in the composition.
- the total content is the total content of two or more sesamin compounds when they are contained.
- the composition of the present invention is preferably taken orally (orally administered).
- the dose (which can also be referred to as ingestion) of the composition of the present invention is not particularly limited.
- the dose of the composition of the present invention may be any amount as long as it can maintain, prevent, suppress or improve the amount of daily activity, and is appropriately set according to the administration form, administration method, body weight of the subject, and the like. do it.
- the total dose of sesamin is 60 kg body weight per day, preferably 0.5 mg or more, more preferably. It is 1 mg or more, more preferably 3 mg or more, preferably 200 mg or less, more preferably 100 mg or less, still more preferably 80 mg or less. In one embodiment, the total dose of sesamin is 60 kg body weight per day for humans (adults), preferably 0.5 to 200 mg, more preferably 1 to 100 mg, still more preferably 3 to 80 mg. It is preferable to ingest or administer the above amount once or more a day, for example, once a day or several times (for example, 2 to 3 times).
- the above amounts of sesamin be orally ingested or administered to humans.
- the compositions of the present invention can be used to allow humans to ingest or administer the above amounts of sesamin per 60 kg of body weight per day.
- the total dose is the total amount when two or more sesamin compounds are used.
- sesamin and / or episesamin is used as the total dose of sesamin and episesamin at a body weight of 60 kg per day, preferably 0.5 to 200 mg, more preferably 1 to 100 mg, still more preferably 3 to 80 mg, human ( It is preferable to ingest or administer it orally to an adult).
- composition of the present invention is preferably continuously ingested or administered. It is expected that the above effects will be enhanced by continuously ingesting or administering sesamin.
- the composition of the present invention is preferably ingested or administered continuously for 1 week or longer, more preferably 4 weeks or longer, further preferably 8 weeks or longer, and particularly preferably 12 weeks or longer. preferable.
- the subject to ingest or administer the composition of the present invention is not particularly limited, and can be ingested by humans and non-human animals.
- non-human animals include industrial animals, pets, laboratory animals and the like.
- industrial animals include livestock such as cattle, horses, pigs, goats and sheep, poultry such as chickens, ducks, quail, turkeys and ostriches, as well as yellowtail, hamachi, madai, maji, koi, nigga and eel.
- Pets are so-called companion animals such as dogs, cats, marmosets, small birds and hamsters, and companion animals. And represents animals used for research in fields such as pharmacy.
- the administration target of the composition of the present invention is preferably a human or a non-human mammal, and more preferably a human.
- the administration target includes a subject who needs or desires to maintain, prevent a decrease in the amount of daily activity, suppress or suppress the decrease, or abide.
- targets include, for example, middle-aged and elderly people, subjects who need or desire to maintain, prevent decline, suppress decline or improve living activity amount and / or daily activity time, and decrease vitality or energy to perform daily activities.
- the middle-aged person may be, for example, a person aged 40 years or older.
- Middle-aged and elderly people are a concept that includes elderly people. Among the middle-aged and elderly people in one aspect, the elderly are preferable as the target.
- the elderly person may be, for example, a person aged 60 years or older or a person aged 65 years or older.
- the composition of the present invention is used, for example, for a healthy person for the purpose of maintaining, preventing, suppressing or improving the amount of daily activity and / or the time of daily living, for the purpose of preventing or preventing a symptom or disease that can be expected to be prevented or improved. It can also be used.
- composition of the present invention may be labeled with a function exerted by maintaining, preventing, suppressing or improving the amount of daily activity and / or the time of daily living.
- Such indications include, for example, "maintaining or improving the amount of daily activity that decreases with age”, “maintaining or extending the time of daily living that decreases with age”, and “maintaining or extending the amount of inactivity that increases with age”.
- the composition of the present invention is preferably a food or drink with the above indication. Further, the above display may be a display to the effect that it is used to obtain the above function.
- the present invention also includes the following methods.
- the present invention also includes the following uses.
- the methods and uses may be therapeutic or non-therapeutic methods or uses.
- By administering one or more kinds of sesamin to a subject it is possible to maintain, prevent, suppress or improve the amount of daily activity and / or the time of daily activity.
- sesamins and preferred embodiments thereof are the same as the compositions of the present invention described above.
- one or more kinds of sesamin one kind of compound of sesamin may be used, and two or more kinds may be used.
- the above use is preferably in humans or non-human mammals, more preferably in humans.
- sesamin in an amount (which can be said to be an effective amount) that can obtain a desired action may be used.
- the preferred dose of sesamin, the subject of administration, and the like are the same as those of the composition of the present invention described above.
- the sesamin may be administered as it is, or may be administered as a composition containing the sesamin.
- the composition of the present invention described above may be used.
- the present invention also includes the use of one or more sesamins for producing the compositions of the present invention. All academic and patent documents described herein are incorporated herein by reference.
- Example 1 Sesamin / episesamin mixture (1: 1) Effect of suppressing decrease in activities of daily living (in vivo test)> Since this experiment is performed under the condition that no exercise load is applied, it is considered that all the measured activity amounts correspond to the daily activity amount in humans.
- the normal feed group and the sesamin / episesamin-containing feed group were divided into groups so that the amount of daily activities was equal.
- An acceleration measuring instrument nanotag manufactured by Kissei Comtec Co., Ltd. was used to measure the amount of daily activities.
- the amount of activity during the active period was measured for 3 days.
- the number of vibrations above a certain intensity was continuously measured, and the total number of frequencies was taken as the amount of daily activity.
- the group fed with the normal feed was the old-age normal feed group (normal feed group), and the group fed with the feed containing 0.1% by weight sesamin and episesamin was the old-age sesamin / episesamin-containing feed group (sesamin / episesamin-containing feed).
- sesamin: episesamin (weight ratio) 1:
- Rats that were determined to be difficult to continue the study by regularly measuring food intake and body weight to understand the health of the animals were subjected to appropriate euthanasia and excluded from the analysis.
- the final analysis subjects were 4 animals in the old-age normal feed group and 6 animals in the old-age sesamin / episesamin-containing feed group.
- FIG. 1 shows the change in the relative activity of daily living when the activity of daily living before the start of the test meal is 1.
- ⁇ is an old-age normal feed group
- ⁇ is an old-age sesamin / episesamin-containing feed group (*: p ⁇ 0.05, repeated measures two-way ANOVA for the old-age normal feed group). The lower the value, the lower the activity.
- the amount of daily activity decreased with aging.
- Example 2 Sesamin or episesamin alone administration has an effect of suppressing a decrease in activities of daily living (in vivo test)>
- Example 2 is a test for examining whether sesamin or episesamin contributes more to the suppression of decrease in activities of daily living. The basic operation was carried out according to Example 1. A group in which 14-month-old Slc: SD male rats were fed a normal diet (CE-2, manufactured by Nippon Claire Co., Ltd.) or a diet containing 0.1% sesamin or episesamin so that the amount of activity was equal. The animals were divided into groups (3 animals / group), and each feed (test meal) was ingested for 1 month.
- the amount of daily activity during the active period was measured.
- the final analysis targets were 2 animals in the normal feed group, 3 animals in each of the sesamin-containing feed group and the episesamin-containing feed group.
- Table 1 shows the amount of daily activity of each group one month after ingestion of the test meal, assuming that the amount of daily activity before the start of the test meal is 1. The lower the value, the lower the amount of daily activity. As shown in Table 1, the amount of daily activity decreased in the normal feed group.
- the sesamin-containing feed group and the episesamin-containing feed group the decrease in the amount of daily activity due to aging was suppressed as compared with the normal feed group. In the episesamine-containing diet group, no decrease in daily activity due to aging was observed.
- sesamin and episesamin suppressed the decrease in the amount of daily activity due to aging, and maintained, prevented the decrease, suppressed or improved the amount of daily activity. It was also revealed that the effect was stronger with episesamine.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The purpose of the present invention is to provide: a composition for maintaining or improving a daily life activity amount, or for preventing or suppressing any decrease in a daily life activity amount; a method for maintaining or improving a daily life activity amount, or for preventing or suppressing any decrease in a daily life activity amount; and a use of one or more sesamins for maintaining or improving a daily life activity amount, or for preventing or suppressing any decrease in a daily life activity amount. The present invention relates to a composition that includes one or more sesamins and that is for maintaining or improving a daily life activity amount, or for preventing or suppressing any decrease in a daily life activity amount.
Description
本発明は、生活活動量の維持、低下予防、低下抑制又は改善用組成物に関する。また、本発明は、生活活動量の維持、低下予防、低下抑制又は改善方法、及び、生活活動量の維持、低下予防、低下抑制又は改善のためのセサミン類の１種以上の使用に関する。
The present invention relates to a composition for maintaining, preventing, suppressing or improving the amount of daily activity. The present invention also relates to a method for maintaining, preventing, suppressing or improving the amount of daily activity, and using one or more sesamin for maintaining, preventing, suppressing or improving the amount of daily activity.
近年、日本を含め世界各国において、生活習慣対策が重要な課題となっている。また、日本のような人口構成における高齢者比率が高い国では、健康寿命の延長も重要な課題となっている。このような状況において、継続して運動を実施することにより、生活習慣病予防を行うこと、筋力を向上させ健康寿命の延長を図ることが推進されている。また、最近では、運動の開始よりも心理的ハードルが低く、手軽に開始できるものとして、日常生活の中での身体活動量を増やすことが推奨されている。例えば、通勤・通学時の歩行や家事は、多くの人々が日常生活の中で手軽に行うことができる活動として推奨されている。
In recent years, lifestyle-related measures have become an important issue in countries around the world, including Japan. In a country like Japan, where the proportion of elderly people is high, extending healthy life expectancy is also an important issue. Under such circumstances, continuous exercise is being promoted to prevent lifestyle-related diseases, improve muscle strength, and extend healthy life expectancy. Recently, it has been recommended to increase the amount of physical activity in daily life as it has a lower psychological hurdle than the start of exercise and can be started easily. For example, walking and housework while commuting to work or school are recommended as activities that many people can easily perform in their daily lives.
ここで、厚生労働省から発行されている「健康づくりのための運動指針２００６」によると、身体活動とは、「安静にしている状態より多くのエネルギーを消費する全ての営みのこと」であり、運動と生活活動に分類できると定義されている。生活活動とは、「身体活動のうち運動以外のもの」と定義されている。また、身体活動の強度と活動を行った時間をかけ合わせて、身体活動量と表現される。
Here, according to the "Exercise Guidelines for Health Promotion 2006" issued by the Ministry of Health, Labor and Welfare, physical activity is "all activities that consume more energy than in a resting state". It is defined that it can be classified into exercise and daily activities. Living activities are defined as "physical activities other than exercise." In addition, the amount of physical activity is expressed by multiplying the intensity of physical activity and the time during which the activity was performed.
また、厚生労働省から発行されている厚生労働白書（平成２６年版）では、健康寿命は、「健康上の問題で日常生活が制限されることなく生活できる期間」と定義されており、介護を必要としない生活を送れる期間は、生活活動が制限されない期間と同義である。ここで、加齢に伴い、生活活動に障害が生じる可能性は高くなる。例えば、非特許文献１には、加齢に伴い、生活活動が減ることが開示されている。非特許文献３には、身体活動量が高いほど、健康寿命が延伸することが開示されている。高齢化社会においては、運動だけでなく生活活動量を維持することで身体活動量を維持し、健康寿命期間を延伸することが求められている。
In addition, the White Paper on Health, Labor and Welfare (2014 edition) issued by the Ministry of Health, Labor and Welfare defines healthy life expectancy as "a period in which daily life is not restricted due to health problems" and requires long-term care. The period during which you can live a life without life is synonymous with the period during which your living activities are not restricted. Here, with aging, there is a high possibility that life activities will be impaired. For example, Non-Patent Document 1 discloses that daily activities decrease with aging. Non-Patent Document 3 discloses that the higher the amount of physical activity, the longer the healthy life expectancy. In an aging society, it is required to maintain physical activity and extend healthy life expectancy by maintaining not only exercise but also daily activity.
また、ヒトの身体活動量は、歩数を基本指標として測定が可能である。例えば、動物試験では、赤外線による移動回数の測定や、テレメトリーによる移動距離の測定などが主流である。しかし、運動を含まない生活活動量の評価には低強度の活動評価も必要となる。近年、ヒトの生活活動量測定法としての三軸加速度センサー内蔵活動量計を利用した測定法が開発された。この測定方法を使うことで低強度の活動も正確に測定できるため、生活活動量をより正確に測定した指標となりうる。この測定法を用いて、ヒトの生活活動量が加齢に伴い低下することが証明された（非特許文献１）。
In addition, the amount of human physical activity can be measured using the number of steps as a basic index. For example, in animal tests, the measurement of the number of movements by infrared rays and the measurement of the movement distance by telemetry are the mainstream. However, low-intensity activity evaluation is also required to evaluate the amount of daily activity that does not include exercise. In recent years, a measurement method using an activity meter with a built-in triaxial accelerometer has been developed as a method for measuring the amount of daily living activity of humans. Since low-intensity activity can be accurately measured by using this measurement method, it can be an index for more accurately measuring the amount of daily activity. Using this measurement method, it was proved that the amount of daily activity in humans decreases with aging (Non-Patent Document 1).
セサミンは、高脂肪食を与えたラットに運動負荷試験を行い、持久力低下が抑制されることが非特許文献２において証明されている。しかし、セサミン類が、身体活動のうち、運動ではなく、生活活動量の低下を予防し、生活活動量維持に寄与するかについては報告されていない。すなわち、セサミンなどのセサミン類が、生活活動量維持作用を有することは知られていなかった。特に、セサミンなどのセサミン類が、加齢に伴う生活活動量維持に寄与するかについては報告されていない。
Sesamin was subjected to an exercise stress test on rats fed a high-fat diet, and it has been proved in Non-Patent Document 2 that the decrease in endurance is suppressed. However, it has not been reported whether sesamins prevent a decrease in the amount of daily activity, not exercise, and contribute to the maintenance of the amount of daily activity among physical activities. That is, it was not known that sesamin such as sesamin has an action of maintaining the amount of daily activity. In particular, it has not been reported whether sesamin such as sesamin contributes to the maintenance of activities of daily living with aging.
本発明は、生活活動量の維持、低下予防、低下抑制又は改善用組成物を提供することを目的とする。また、本発明は、生活活動量の維持、低下予防、低下抑制又は改善方法、及び、生活活動量の維持、低下予防、低下抑制又は改善のためのセサミン類の１種以上の使用を目的とする。
An object of the present invention is to provide a composition for maintaining, preventing, suppressing or improving the amount of daily activity. Another object of the present invention is to maintain, prevent a decrease in the amount of daily activity, suppress or improve the decrease, and use one or more sesamin for maintaining, preventing the decrease, suppressing or ameliorating the amount of daily activity. To do.
本発明者らは上記課題を解決すべく鋭意検討し、非特許文献１に示される三軸加速度センサー内蔵活動量計を利用し、運動を負荷せずにラットの活動量を測定することにより、セサミン類が運動を除く身体活動量すなわち生活活動量を維持する作用を有することを見出した。また本発明者らは、セサミン類が、加齢により低下する生活活動量の低下予防又は維持に有用であることを見出した。
The present inventors diligently studied to solve the above problems, and measured the activity amount of the rat without applying exercise by using the activity meter with a built-in triaxial accelerometer shown in Non-Patent Document 1. It was found that sesamines have the effect of maintaining the amount of physical activity excluding exercise, that is, the amount of living activity. In addition, the present inventors have found that sesamin are useful for preventing or maintaining a decrease in the amount of daily activity that decreases with age.
本発明は、以下の生活活動量の維持、低下予防、低下抑制又は改善用組成物に関する。
〔１〕セサミン類の１種以上を含む生活活動量の維持、低下予防、低下抑制又は改善用組成物。
〔２〕セサミン類の１種以上が、セサミン及び／又はエピセサミンである上記〔１〕に記載の組成物。
〔３〕セサミン類の１種以上が、エピセサミンである上記〔１〕又は〔２〕に記載の組成物。
〔４〕加齢に伴う生活活動量低下の予防若しくは抑制、加齢に伴い低下した生活活動量の改善、加齢に伴う不活動時間増加の予防若しくは抑制、加齢に伴い増加した不活動時間の改善のための上記〔１〕～〔３〕のいずれかに記載の組成物。
〔５〕経口用組成物である上記〔１〕～〔４〕のいずれかに記載の組成物。
〔６〕上記経口用組成物が飲食品、医薬品、医薬部外品又は飼料である上記〔５〕に記載の組成物。
〔７〕上記飲食品が特定保健用食品、栄養機能食品又は機能性表示食品である〔６〕に記載の組成物。
〔８〕セサミン類の１種以上を投与する、生活活動量の維持、低下予防、低下抑制又は改善方法。
〔９〕生活活動量の維持、低下予防、低下抑制又は改善のための、セサミン類の１種以上の使用。 The present invention relates to the following compositions for maintaining, preventing, suppressing or improving the amount of daily activities.
[1] A composition for maintaining, preventing, suppressing or improving the amount of daily activity containing one or more of sesamin.
[2] The composition according to the above [1], wherein one or more of the sesamin species is sesamin and / or episesamin.
[3] The composition according to the above [1] or [2], wherein one or more of the sesamin are episesamin.
[4] Prevention or suppression of decrease in daily activity due to aging, improvement of decrease in daily activity with aging, prevention or suppression of increase in inactivity time with aging, increase in inactivity time with aging The composition according to any one of the above [1] to [3] for improving the above.
[5] The composition according to any one of the above [1] to [4], which is an oral composition.
[6] The composition according to the above [5], wherein the oral composition is a food or drink, a pharmaceutical product, a quasi drug, or a feed.
[7] The composition according to [6], wherein the food or drink is a food for specified health use, a nutritionally functional food, or a food with functional claims.
[8] A method for maintaining, preventing, suppressing, or improving the amount of daily activity by administering one or more of sesamin.
[9] Use of one or more sesamin for maintaining, preventing, suppressing or improving the amount of daily activity.
〔１〕セサミン類の１種以上を含む生活活動量の維持、低下予防、低下抑制又は改善用組成物。
〔２〕セサミン類の１種以上が、セサミン及び／又はエピセサミンである上記〔１〕に記載の組成物。
〔３〕セサミン類の１種以上が、エピセサミンである上記〔１〕又は〔２〕に記載の組成物。
〔４〕加齢に伴う生活活動量低下の予防若しくは抑制、加齢に伴い低下した生活活動量の改善、加齢に伴う不活動時間増加の予防若しくは抑制、加齢に伴い増加した不活動時間の改善のための上記〔１〕～〔３〕のいずれかに記載の組成物。
〔５〕経口用組成物である上記〔１〕～〔４〕のいずれかに記載の組成物。
〔６〕上記経口用組成物が飲食品、医薬品、医薬部外品又は飼料である上記〔５〕に記載の組成物。
〔７〕上記飲食品が特定保健用食品、栄養機能食品又は機能性表示食品である〔６〕に記載の組成物。
〔８〕セサミン類の１種以上を投与する、生活活動量の維持、低下予防、低下抑制又は改善方法。
〔９〕生活活動量の維持、低下予防、低下抑制又は改善のための、セサミン類の１種以上の使用。 The present invention relates to the following compositions for maintaining, preventing, suppressing or improving the amount of daily activities.
[1] A composition for maintaining, preventing, suppressing or improving the amount of daily activity containing one or more of sesamin.
[2] The composition according to the above [1], wherein one or more of the sesamin species is sesamin and / or episesamin.
[3] The composition according to the above [1] or [2], wherein one or more of the sesamin are episesamin.
[4] Prevention or suppression of decrease in daily activity due to aging, improvement of decrease in daily activity with aging, prevention or suppression of increase in inactivity time with aging, increase in inactivity time with aging The composition according to any one of the above [1] to [3] for improving the above.
[5] The composition according to any one of the above [1] to [4], which is an oral composition.
[6] The composition according to the above [5], wherein the oral composition is a food or drink, a pharmaceutical product, a quasi drug, or a feed.
[7] The composition according to [6], wherein the food or drink is a food for specified health use, a nutritionally functional food, or a food with functional claims.
[8] A method for maintaining, preventing, suppressing, or improving the amount of daily activity by administering one or more of sesamin.
[9] Use of one or more sesamin for maintaining, preventing, suppressing or improving the amount of daily activity.
本発明によると生活活動量の維持、低下予防、低下抑制又は改善用組成物を提供することができる。また、本発明によれば、生活活動量の維持、低下予防、低下抑制又は改善方法を提供することができる。また、本発明によれば、生活活動量の維持、低下予防、低下抑制又は改善のためのセサミン類の１種以上の使用を提供することができる。
セサミン類の１種以上を摂取すると、生活活動量の維持、低下予防、低下抑制又は改善の効果が得られる。また、セサミン類の１種以上を摂取すると、加齢に伴う生活活動量の低下の予防若しくは抑制、加齢に伴い低下した生活活動量の改善、又は、加齢に伴う不活動時間増加の予防、抑制若しくは改善をすることができる。本発明で使用されるセサミン類は、古くから食品として摂取されてきた成分であり、安全性が高く継続的に摂取できる点でも有利である。 According to the present invention, it is possible to provide a composition for maintaining, preventing, suppressing or improving the amount of daily activity. Further, according to the present invention, it is possible to provide a method for maintaining, preventing, suppressing or improving the amount of daily activity. Further, according to the present invention, it is possible to provide the use of one or more kinds of sesamin for maintaining, preventing, suppressing or improving the amount of daily activity.
Ingestion of one or more of sesamin has the effect of maintaining, preventing, suppressing or improving the amount of daily activity. Ingestion of one or more sesamin species prevents or suppresses the decrease in daily activity due to aging, improves the decrease in daily activity due to aging, or prevents the increase in inactivity time due to aging. , Can be suppressed or improved. The sesamin used in the present invention is a component that has been ingested as a food for a long time, and is also advantageous in that it is highly safe and can be continuously ingested.
セサミン類の１種以上を摂取すると、生活活動量の維持、低下予防、低下抑制又は改善の効果が得られる。また、セサミン類の１種以上を摂取すると、加齢に伴う生活活動量の低下の予防若しくは抑制、加齢に伴い低下した生活活動量の改善、又は、加齢に伴う不活動時間増加の予防、抑制若しくは改善をすることができる。本発明で使用されるセサミン類は、古くから食品として摂取されてきた成分であり、安全性が高く継続的に摂取できる点でも有利である。 According to the present invention, it is possible to provide a composition for maintaining, preventing, suppressing or improving the amount of daily activity. Further, according to the present invention, it is possible to provide a method for maintaining, preventing, suppressing or improving the amount of daily activity. Further, according to the present invention, it is possible to provide the use of one or more kinds of sesamin for maintaining, preventing, suppressing or improving the amount of daily activity.
Ingestion of one or more of sesamin has the effect of maintaining, preventing, suppressing or improving the amount of daily activity. Ingestion of one or more sesamin species prevents or suppresses the decrease in daily activity due to aging, improves the decrease in daily activity due to aging, or prevents the increase in inactivity time due to aging. , Can be suppressed or improved. The sesamin used in the present invention is a component that has been ingested as a food for a long time, and is also advantageous in that it is highly safe and can be continuously ingested.
本発明の生活活動量の維持、低下予防、低下抑制又は改善用組成物は、セサミン類の１種以上を含む。
セサミン類は、胡麻の主要なリグナン類化合物の一種で、胡麻中に０．５～１．０重量％程度含まれている。人工的に合成された化合物の長期的摂取は、予期せぬ副作用等の観点から好ましくない一方で、安全性の担保されたセサミン類は、長期的摂取に最適である。 The composition for maintaining, preventing, suppressing or improving the amount of daily activity of the present invention contains one or more sesamin.
Sesamin is one of the main lignan compounds of sesame, and is contained in sesame in an amount of about 0.5 to 1.0% by weight. While long-term ingestion of artificially synthesized compounds is not preferable from the viewpoint of unexpected side effects and the like, sesamins whose safety is guaranteed are most suitable for long-term ingestion.
セサミン類は、胡麻の主要なリグナン類化合物の一種で、胡麻中に０．５～１．０重量％程度含まれている。人工的に合成された化合物の長期的摂取は、予期せぬ副作用等の観点から好ましくない一方で、安全性の担保されたセサミン類は、長期的摂取に最適である。 The composition for maintaining, preventing, suppressing or improving the amount of daily activity of the present invention contains one or more sesamin.
Sesamin is one of the main lignan compounds of sesame, and is contained in sesame in an amount of about 0.5 to 1.0% by weight. While long-term ingestion of artificially synthesized compounds is not preferable from the viewpoint of unexpected side effects and the like, sesamins whose safety is guaranteed are most suitable for long-term ingestion.
本発明において、身体活動、運動、及び、生活活動は、厚生労働省から発行されている「健康づくりのための運動指針２００６」における身体活動、運動、及び、生活活動の定義と同一の意味である。すなわち、身体活動とは、安静にしている状態より多くのエネルギーを消費するすべての営みのことであり、生活活動は、身体活動のうち運動以外のものである。なお運動は、例えば、体力の維持・向上を目的として計画的・意図的に実施するものである。生活活動量は、例えば、ヒトにおいては三軸加速度センサー内蔵活動量計（ｐａｎａｓｏｎｉｃ社製 Ａｃｔｉｍａｒｋｅｒ）を用いて測定することができる。動物においてはトレッドミルなどの運動を負荷しない条件で三軸加速度センサー内蔵活動量計（キッセイコムテック（株）社製 ｎａｎｏｔａｇ）を用いて測定することができる。
In the present invention, physical activity, exercise, and living activity have the same meaning as the definitions of physical activity, exercise, and living activity in the "Exercise Guideline for Health Promotion 2006" issued by the Ministry of Health, Labor and Welfare. .. That is, physical activity is all activities that consume more energy than in a resting state, and living activities are physical activities other than exercise. The exercise is carried out systematically and intentionally for the purpose of maintaining and improving physical fitness, for example. For example, in humans, the amount of daily activity can be measured using an activity meter with a built-in triaxial accelerometer (Actimarker manufactured by Panasonic Corporation). Animals can be measured using an activity meter with a built-in triaxial accelerometer (nanotag manufactured by Kissei Comtech Co., Ltd.) under conditions such as a treadmill that do not impose exercise.
本発明における生活活動としては、特に限定されないが、例えば、ヒトにおいては、家事、仕事及び／又は育児上の活動などが挙げられる。動物においては、運動を負荷しない条件で測定した活動量がヒトでいう生活活動量に相当すると考えられる。
The life activity in the present invention is not particularly limited, and examples thereof include household chores, work and / or childcare activities in humans. In animals, the amount of activity measured under the condition that no exercise is applied is considered to correspond to the amount of daily activity in humans.
また、本発明において、生活活動量は、生活活動量及び／又は生活活動時間として測定することができる。すなわち、生活活動量の維持、低下予防、低下抑制又は改善は、生活活動量及び／又は生活活動時間の維持、低下予防、低下抑制又は改善を意味する。
なお、生活活動時間の低下（減少）によって、不活動時間が増加するため、本発明における生活活動量の維持、低下予防、低下抑制又は改善には、不活動時間増加の予防、抑制又は改善も含まれる。なお、本明細書において不活動時間とは、身体活動を行っていない時間、すなわち、睡眠や座位行動など安静にしている時間を意味する。 Further, in the present invention, the amount of daily activity can be measured as the amount of daily activity and / or the time of daily activity. That is, maintenance, prevention of decrease, suppression or improvement of decrease in the amount of daily activity means maintenance, prevention of decrease, suppression or improvement of decrease in amount of daily activity and / or living activity time.
Since the inactivity time increases due to the decrease (decrease) in the living activity time, the prevention, suppression or improvement of the increase in the inactivity time is also used for maintaining, preventing the decrease, suppressing or improving the amount of living activity in the present invention. included. In the present specification, the inactivity time means a time during which physical activity is not performed, that is, a time during rest such as sleeping or sitting behavior.
なお、生活活動時間の低下（減少）によって、不活動時間が増加するため、本発明における生活活動量の維持、低下予防、低下抑制又は改善には、不活動時間増加の予防、抑制又は改善も含まれる。なお、本明細書において不活動時間とは、身体活動を行っていない時間、すなわち、睡眠や座位行動など安静にしている時間を意味する。 Further, in the present invention, the amount of daily activity can be measured as the amount of daily activity and / or the time of daily activity. That is, maintenance, prevention of decrease, suppression or improvement of decrease in the amount of daily activity means maintenance, prevention of decrease, suppression or improvement of decrease in amount of daily activity and / or living activity time.
Since the inactivity time increases due to the decrease (decrease) in the living activity time, the prevention, suppression or improvement of the increase in the inactivity time is also used for maintaining, preventing the decrease, suppressing or improving the amount of living activity in the present invention. included. In the present specification, the inactivity time means a time during which physical activity is not performed, that is, a time during rest such as sleeping or sitting behavior.
上記生活活動量の維持、低下予防、低下抑制又は改善は、生活活動量低下の予防若しくは抑制、低下した生活活動量の改善、不活動時間増加の予防若しくは抑制、又は、増加した不活動時間の改善であることが好ましい。
The above-mentioned maintenance, prevention of decrease, suppression or improvement of decrease in daily activity means prevention or suppression of decrease in daily activity, improvement of decreased daily activity, prevention or suppression of increase in inactivity time, or increased inactivity time. It is preferable that it is an improvement.
また、上記生活活動量の維持、低下予防、低下抑制又は改善が、加齢に伴う生活活動量低下の予防若しくは抑制、加齢に伴い低下した生活活動量の改善、加齢に伴う不活動時間増加の予防若しくは抑制、加齢に伴い増加した不活動時間の改善であることが好ましい。
なお、本発明において加齢とは、中高年以降、特に４０歳前後以降の年齢の増加に伴う変化のことをいう。 In addition, the maintenance, prevention of decrease, suppression or improvement of the above-mentioned amount of daily activity is the prevention or suppression of the decrease in the amount of daily activity associated with aging, the improvement of the amount of daily activity decreased with aging, and the inactivity time associated with aging. It is preferable to prevent or suppress the increase and improve the inactivity time that has increased with aging.
In the present invention, aging refers to a change associated with an increase in age after middle and old age, especially after about 40 years old.
なお、本発明において加齢とは、中高年以降、特に４０歳前後以降の年齢の増加に伴う変化のことをいう。 In addition, the maintenance, prevention of decrease, suppression or improvement of the above-mentioned amount of daily activity is the prevention or suppression of the decrease in the amount of daily activity associated with aging, the improvement of the amount of daily activity decreased with aging, and the inactivity time associated with aging. It is preferable to prevent or suppress the increase and improve the inactivity time that has increased with aging.
In the present invention, aging refers to a change associated with an increase in age after middle and old age, especially after about 40 years old.
（セサミン類）
本発明において、セサミン類とは、セサミン及びその類縁体を含む化合物の総称である。セサミンは、ゴマに含まれる主要なリグナン化合物の一種である。セサミン類縁体としては、エピセサミンの他、例えば特開平４－９３３１号公報に記載されたジオキサビシクロ［３．３．０］オクタン誘導体が挙げられる。セサミン類の１種以上として、化合物１種を単独で用いてもよく、２種以上を用いてもよい。セサミン類の具体例としては、セサミン、エピセサミン、セサミノール、エピセサミノール、セサモール、セサモリン等を例示でき、これらの立体異性体又はラセミ体を単独で、または混合して使用することができる。また、セサミン類の代謝物（例えば、特開２００１－１３９５７９号公報に記載）も、本発明の効果を示す限り、本発明のセサミン類に含まれるセサミン類縁体であり、本発明に使用することができる。本発明においては、セサミン類の１種以上として、セサミン及び／又はエピセサミンを好適に用いることができ、セサミン及びエピセサミン、又は、エピセサミンをより好適に用いることができ、エピセサミンをさらに好ましく用いることができる。セサミン及びエピセサミンを用いる場合、これらの比率は特に限定されないが、例えば、セサミン：エピセサミン（重量比）が１：０．１～１：９が好ましく、１：０．３～１：３がより好ましく、１：０．５～１：２がさらに好ましい。 (Sesamin)
In the present invention, sesamin is a general term for compounds containing sesamin and its analogs. Sesamin is one of the major lignan compounds contained in sesame seeds. Examples of sesamin analogs include episesamin and dioxabicyclo [3.3.0] octane derivatives described in JP-A-4-9331. As one or more kinds of sesamin, one kind of compound may be used alone, or two or more kinds may be used. Specific examples of sesamin include sesamin, episesamine, sesaminol, episesaminol, sesamol, sesamolin and the like, and these stereoisomers or racemates can be used alone or in combination. Further, a metatransformer of sesamin (for example, described in JP-A-2001-139579) is also a sesamin analog contained in the sesamin of the present invention as long as the effect of the present invention is exhibited, and is used in the present invention. Can be done. In the present invention, sesamin and / or episesamin can be preferably used as one or more of the sesamin, sesamin and episesamin, or episesamin can be more preferably used, and episesamin can be further preferably used. .. When sesamin and episesamin are used, their ratios are not particularly limited, but for example, sesamin: episesamin (weight ratio) is preferably 1: 0.1 to 1: 9, and more preferably 1: 0.3 to 1: 3. , 1: 0.5 to 1: 2 is more preferable.
本発明において、セサミン類とは、セサミン及びその類縁体を含む化合物の総称である。セサミンは、ゴマに含まれる主要なリグナン化合物の一種である。セサミン類縁体としては、エピセサミンの他、例えば特開平４－９３３１号公報に記載されたジオキサビシクロ［３．３．０］オクタン誘導体が挙げられる。セサミン類の１種以上として、化合物１種を単独で用いてもよく、２種以上を用いてもよい。セサミン類の具体例としては、セサミン、エピセサミン、セサミノール、エピセサミノール、セサモール、セサモリン等を例示でき、これらの立体異性体又はラセミ体を単独で、または混合して使用することができる。また、セサミン類の代謝物（例えば、特開２００１－１３９５７９号公報に記載）も、本発明の効果を示す限り、本発明のセサミン類に含まれるセサミン類縁体であり、本発明に使用することができる。本発明においては、セサミン類の１種以上として、セサミン及び／又はエピセサミンを好適に用いることができ、セサミン及びエピセサミン、又は、エピセサミンをより好適に用いることができ、エピセサミンをさらに好ましく用いることができる。セサミン及びエピセサミンを用いる場合、これらの比率は特に限定されないが、例えば、セサミン：エピセサミン（重量比）が１：０．１～１：９が好ましく、１：０．３～１：３がより好ましく、１：０．５～１：２がさらに好ましい。 (Sesamin)
In the present invention, sesamin is a general term for compounds containing sesamin and its analogs. Sesamin is one of the major lignan compounds contained in sesame seeds. Examples of sesamin analogs include episesamin and dioxabicyclo [3.3.0] octane derivatives described in JP-A-4-9331. As one or more kinds of sesamin, one kind of compound may be used alone, or two or more kinds may be used. Specific examples of sesamin include sesamin, episesamine, sesaminol, episesaminol, sesamol, sesamolin and the like, and these stereoisomers or racemates can be used alone or in combination. Further, a metatransformer of sesamin (for example, described in JP-A-2001-139579) is also a sesamin analog contained in the sesamin of the present invention as long as the effect of the present invention is exhibited, and is used in the present invention. Can be done. In the present invention, sesamin and / or episesamin can be preferably used as one or more of the sesamin, sesamin and episesamin, or episesamin can be more preferably used, and episesamin can be further preferably used. .. When sesamin and episesamin are used, their ratios are not particularly limited, but for example, sesamin: episesamin (weight ratio) is preferably 1: 0.1 to 1: 9, and more preferably 1: 0.3 to 1: 3. , 1: 0.5 to 1: 2 is more preferable.
本発明で使用されるセサミン類は、その形態や製造方法等によって、何ら制限されるものではない。例えば、セサミンの場合は、ゴマ油から公知の方法（例えば、特開平４－９３３１号公報に記載された方法）によって抽出したセサミン（セサミン抽出物または精製物という）を用いることができる。また、市販のゴマ油（液状）をそのまま用いることもできる。しかしながら、ゴマ油を用いた場合には、ゴマ油特有の風味が官能的に好ましくないと評価されることもあることから、ゴマ油から抽出された無味無臭であるセサミン抽出物（又はセサミン精製物）を用いることが好ましい。また、ゴマ油を用いた場合、セサミン含有量が低いため、好ましい量のセサミンを配合しようとすると、処方される組成物の単位投与当りの体積が大きくなり過ぎるため、摂取に不都合を生じることがある。特に、経口投与用に製剤化した場合は、製剤（錠剤、カプセルなど）が大きくなり過ぎて摂取に支障が生じる。したがって、摂取量が少なくてよいという観点からもゴマ油からのセサミン抽出物（又はセサミン精製物）を用いることが好ましい。本発明においては、精製又は単離されたセサミン類の１種以上を使用してもよい。合成によりセサミン類を得ることもできる。その方法としては、例えば、セサミン、エピセサミンについては、Ｂｅｒｏｚａらの方法（Ｊ．Ａｍ．Ｃｈｅｍ．Ｓｏｃ．，７８，１２４２（１９５６））で合成することができる。セサミン、エピセサミンの代謝物についてはＵｒａｔａらの方法（Ｃｈｅｍ．Ｐｈａｒｍ．Ｂｕｌｌ．（Ｔｏｋｙｏ），５６（１１）１６１１－２（２００８））で合成することができる。
The sesamin used in the present invention is not limited by its form, production method, or the like. For example, in the case of sesamin, sesamin (referred to as sesamin extract or purified product) extracted from sesame oil by a known method (for example, the method described in JP-A-4-9331) can be used. Alternatively, commercially available sesame oil (liquid) can be used as it is. However, when sesame oil is used, the flavor peculiar to sesame oil may be evaluated as sensually unfavorable. Therefore, a tasteless and odorless sesamin extract (or refined sesamin product) extracted from sesame oil is used. Is preferable. In addition, when sesame oil is used, the sesamin content is low, and if a preferable amount of sesamin is to be added, the volume of the prescribed composition per unit dose becomes too large, which may cause inconvenience in intake. .. In particular, when formulated for oral administration, the formulation (tablets, capsules, etc.) becomes too large, which hinders ingestion. Therefore, it is preferable to use a sesamin extract (or a purified sesamin product) from sesame oil from the viewpoint that the intake amount may be small. In the present invention, one or more of purified or isolated sesamin may be used. Sesamin can also be obtained by synthesis. As the method, for example, sesamin and episesamin can be synthesized by the method of Beroza et al. (J. Am. Chem. Soc., 78, 1242 (1956)). The metabolites of sesamin and episesamin can be synthesized by the method of Urata et al. (Chem. Pharm. Bull. (Tokyo), 56 (11) 1611-2 (2008)).
セサミン類は、天然物や飲食品に含まれ、食経験がある化合物である。このため安全性の観点から、セサミン類は、例えば毎日摂取することにも問題が少ないと考えられる。本発明によれば、安全性が高い物質を有効成分として含む生活活動量の維持、低下予防、低下抑制又は改善用組成物を提供することができる。
Sesamin is a compound that is contained in natural products and foods and drinks and has eating experience. Therefore, from the viewpoint of safety, sesamin is considered to have few problems in ingestion every day, for example. According to the present invention, it is possible to provide a composition for maintaining, preventing, suppressing or improving the amount of daily activity containing a highly safe substance as an active ingredient.
本発明の組成物は、治療的用途（医療用途）又は非治療的用途（非医療用途）のいずれにも適用することができる。非治療的とは、医療行為、すなわち人間の手術、治療又は診断を含まない概念である。
本発明の組成物は、飲食品、医薬品、医薬部外品、飼料等の形態とすることができる。本発明の組成物は、それ自体が生活活動量の維持、低下予防、低下抑制又は改善のための飲食品、医薬品、医薬部外品、飼料等であってもよく、これらに配合して使用される素材又は製剤等であってもよい。
本発明の組成物は、一例として、剤の形態で提供することができるが、本形態に限定されるものではない。当該剤をそのまま組成物として、又は、当該剤を含む組成物として提供することもできる。
本発明の組成物は、経口用組成物、非経口用組成物のいずれであってもよいが、好ましくは経口用組成物である。経口用組成物としては、飲食品、経口用の医薬品、医薬部外品、飼料が挙げられ、好ましくは飲食品又は経口用医薬品であり、より好ましくは飲食品である。 The composition of the present invention can be applied to either therapeutic use (medical use) or non-therapeutic use (non-medical use). Non-therapeutic is a concept that does not include medical practice, ie human surgery, treatment or diagnosis.
The composition of the present invention can be in the form of food and drink, pharmaceuticals, quasi-drugs, feed and the like. The composition of the present invention may itself be a food or drink, a drug, a quasi-drug, a feed, etc. for maintaining, preventing, suppressing or improving the amount of daily activity, and is used in combination with these. It may be a material or a preparation to be used.
The composition of the present invention can be provided, for example, in the form of an agent, but is not limited to this form. The agent can be provided as it is as a composition or as a composition containing the agent.
The composition of the present invention may be either an oral composition or a parenteral composition, but is preferably an oral composition. Examples of the oral composition include foods and drinks, oral medicines, quasi-drugs, and feeds, preferably foods and drinks or oral medicines, and more preferably foods and drinks.
本発明の組成物は、飲食品、医薬品、医薬部外品、飼料等の形態とすることができる。本発明の組成物は、それ自体が生活活動量の維持、低下予防、低下抑制又は改善のための飲食品、医薬品、医薬部外品、飼料等であってもよく、これらに配合して使用される素材又は製剤等であってもよい。
本発明の組成物は、一例として、剤の形態で提供することができるが、本形態に限定されるものではない。当該剤をそのまま組成物として、又は、当該剤を含む組成物として提供することもできる。
本発明の組成物は、経口用組成物、非経口用組成物のいずれであってもよいが、好ましくは経口用組成物である。経口用組成物としては、飲食品、経口用の医薬品、医薬部外品、飼料が挙げられ、好ましくは飲食品又は経口用医薬品であり、より好ましくは飲食品である。 The composition of the present invention can be applied to either therapeutic use (medical use) or non-therapeutic use (non-medical use). Non-therapeutic is a concept that does not include medical practice, ie human surgery, treatment or diagnosis.
The composition of the present invention can be in the form of food and drink, pharmaceuticals, quasi-drugs, feed and the like. The composition of the present invention may itself be a food or drink, a drug, a quasi-drug, a feed, etc. for maintaining, preventing, suppressing or improving the amount of daily activity, and is used in combination with these. It may be a material or a preparation to be used.
The composition of the present invention can be provided, for example, in the form of an agent, but is not limited to this form. The agent can be provided as it is as a composition or as a composition containing the agent.
The composition of the present invention may be either an oral composition or a parenteral composition, but is preferably an oral composition. Examples of the oral composition include foods and drinks, oral medicines, quasi-drugs, and feeds, preferably foods and drinks or oral medicines, and more preferably foods and drinks.
本発明の組成物は、本発明の効果を損なわない限り、セサミン類の１種以上に加えて、任意の添加剤、任意の成分を含有することができる。これらの添加剤及び成分は、組成物の形態等に応じて選択することができ、一般的に飲食品、医薬品、医薬部外品、飼料等に使用可能なものが使用できる。本発明の組成物を、飲食品、医薬品、医薬部外品、飼料等とする場合、その製造方法は特に限定されず、一般的な方法により製造することができる。
The composition of the present invention may contain any additive and any component in addition to one or more sesamins as long as the effects of the present invention are not impaired. These additives and ingredients can be selected according to the form of the composition and the like, and generally those that can be used for foods and drinks, pharmaceuticals, quasi-drugs, feeds and the like can be used. When the composition of the present invention is a food or drink, a pharmaceutical product, a quasi-drug, a feed or the like, the production method thereof is not particularly limited and can be produced by a general method.
例えば本発明の組成物を飲食品とする場合、セサミン類の１種以上に、飲食品に使用可能な成分（例えば、食品素材、必要に応じて使用される食品添加物等）を配合して、種々の飲食品とすることができる。飲食品は特に限定されず、例えば、一般的な飲食品、健康食品、健康補助食品、健康飲料、機能性表示食品、特定保健用食品、病者用飲食品等が挙げられる。上記健康食品、健康補助食品、機能性表示食品、特定保健用食品等は、例えば、細粒剤、錠剤、顆粒剤、散剤、カプセル剤、チュアブル剤、ドライシロップ剤、シロップ剤、液剤、飲料、流動食等の各種製剤形態として使用することができる。
For example, when the composition of the present invention is used as a food or drink, one or more kinds of sesamin are mixed with ingredients that can be used in the food or drink (for example, food materials, food additives used as needed, etc.). , Various foods and drinks can be used. Foods and drinks are not particularly limited, and examples thereof include general foods and drinks, health foods, dietary supplements, health drinks, foods with functional claims, foods for specified health use, foods and drinks for the sick, and the like. The above-mentioned health foods, health supplements, foods with functional claims, foods for specified health use, etc. include, for example, fine granules, tablets, granules, powders, capsules, chewables, dry syrups, syrups, liquids, beverages, fluids. It can be used as various formulations such as food.
本発明の組成物を医薬品又は医薬部外品とする場合、例えば、セサミン類の１種以上に、薬理学的に許容される担体、必要に応じて添加される添加剤等を配合して、各種剤形の医薬品又は医薬部外品とすることができる。そのような担体、添加剤等は、医薬品又は医薬部外品に使用可能な、薬理学的に許容されるものであればよく、例えば、賦形剤、結合剤、崩壊剤、滑沢剤、抗酸化剤、着色剤等の１又は２以上が挙げられる。医薬品又は医薬部外品の投与（摂取）形態としては、経口又は非経口（経皮、経粘膜、経腸、注射等）投与の形態が挙げられる。本発明の組成物を医薬品又は医薬部外品とする場合、経口用医薬品又は医薬部外品とすることが好ましい。経口投与のための剤形としては、液剤、錠剤、散剤、細粒剤、顆粒剤、糖衣錠、カプセル剤、懸濁液、乳剤、チュアブル剤等が挙げられる。医薬品は、非ヒト動物用医薬であってもよい。
When the composition of the present invention is a pharmaceutical product or a quasi-drug, for example, a pharmacologically acceptable carrier, an additive added as necessary, or the like is blended with one or more of sesamin. It can be a drug of various dosage forms or a quasi-drug. Such carriers, additives and the like may be pharmacologically acceptable as long as they can be used in pharmaceutical products or quasi-drugs, and for example, excipients, binders, disintegrants, lubricants, etc. One or more of antioxidants, colorants and the like can be mentioned. Examples of the administration (ingestion) form of the drug or quasi-drug include oral or parenteral (transdermal, transmucosal, intestinal, injection, etc.) administration forms. When the composition of the present invention is a drug or a quasi-drug, it is preferably an oral drug or a quasi-drug. Dosage forms for oral administration include liquids, tablets, powders, fine granules, granules, sugar-coated tablets, capsules, suspensions, emulsions, chewables and the like. The drug may be a non-human veterinary drug.
本発明の組成物を飼料とする場合には、セサミン類の１種以上を飼料に配合すればよい。飼料には飼料添加剤も含まれる。飼料としては、例えば、牛、豚、鶏、羊、馬等に用いる家畜用飼料；ウサギ、ラット、マウス等に用いる小動物用飼料；犬、猫、小鳥等に用いるペットフードなどが挙げられる。
When the composition of the present invention is used as a feed, one or more of sesamin may be added to the feed. The feed also contains feed additives. Examples of the feed include livestock feed used for cattle, pigs, chickens, sheep, horses and the like; small animal feed used for rabbits, rats, mice and the like; pet food used for dogs, cats, small birds and the like.
本発明の組成物に含まれるセサミン類の含有量は特に限定されず、その形態等に応じて設定することができる。
本発明の組成物中のセサミン類の総含有量は、例えば、該組成物中に０．００１重量％以上が好ましく、０．０１重量％以上がより好ましく、０．０５重量％以上がさらに好ましく、また、１０重量％以下が好ましく、５重量％以下がより好ましい。
一態様において、セサミン類の総含有量は、組成物中に０．００１～１０重量％が好ましく、０．０１～５重量％がより好ましく、０．０５～５重量％がさらに好ましい。
上記総含有量は、セサミン類の化合物を２種以上含有する場合は、これらの合計含有量である。 The content of sesamin contained in the composition of the present invention is not particularly limited and can be set according to the form and the like.
The total content of sesamin in the composition of the present invention is, for example, preferably 0.001% by weight or more, more preferably 0.01% by weight or more, still more preferably 0.05% by weight or more in the composition. , 10% by weight or less is preferable, and 5% by weight or less is more preferable.
In one embodiment, the total content of sesamin is preferably 0.001 to 10% by weight, more preferably 0.01 to 5% by weight, still more preferably 0.05 to 5% by weight in the composition.
The total content is the total content of two or more sesamin compounds when they are contained.
本発明の組成物中のセサミン類の総含有量は、例えば、該組成物中に０．００１重量％以上が好ましく、０．０１重量％以上がより好ましく、０．０５重量％以上がさらに好ましく、また、１０重量％以下が好ましく、５重量％以下がより好ましい。
一態様において、セサミン類の総含有量は、組成物中に０．００１～１０重量％が好ましく、０．０１～５重量％がより好ましく、０．０５～５重量％がさらに好ましい。
上記総含有量は、セサミン類の化合物を２種以上含有する場合は、これらの合計含有量である。 The content of sesamin contained in the composition of the present invention is not particularly limited and can be set according to the form and the like.
The total content of sesamin in the composition of the present invention is, for example, preferably 0.001% by weight or more, more preferably 0.01% by weight or more, still more preferably 0.05% by weight or more in the composition. , 10% by weight or less is preferable, and 5% by weight or less is more preferable.
In one embodiment, the total content of sesamin is preferably 0.001 to 10% by weight, more preferably 0.01 to 5% by weight, still more preferably 0.05 to 5% by weight in the composition.
The total content is the total content of two or more sesamin compounds when they are contained.
本発明の組成物は、経口で摂取（経口投与）されることが好ましい。本発明の組成物の投与量（摂取量ということもできる）は特に限定されない。本発明の組成物の投与量は、生活活動量の維持、低下予防、低下抑制又は改善効果が得られるような量であればよく、投与形態、投与方法、対象の体重等に応じて適宜設定すればよい。
The composition of the present invention is preferably taken orally (orally administered). The dose (which can also be referred to as ingestion) of the composition of the present invention is not particularly limited. The dose of the composition of the present invention may be any amount as long as it can maintain, prevent, suppress or improve the amount of daily activity, and is appropriately set according to the administration form, administration method, body weight of the subject, and the like. do it.
一態様において、本発明の組成物をヒト（成人）を対象に経口で摂取させる又は投与する場合、セサミン類の総投与量は、１日当たり体重６０ｋｇで、好ましくは０．５ｍｇ以上、より好ましくは１ｍｇ以上、さらに好ましくは、３ｍｇ以上、また、好ましくは２００ｍｇ以下、より好ましくは１００ｍｇ以下、さらに好ましくは８０ｍｇ以下である。
一態様において、セサミン類の総投与量は、ヒト（成人）であれば、１日当たり体重６０ｋｇで、好ましくは０．５～２００ｍｇ、より好ましくは１～１００ｍｇ、さらに好ましくは３～８０ｍｇである。
上記量を、１日１回以上、例えば、１日１回又は数回（例えば２～３回）に分けて、摂取させる又は投与することが好ましい。
一態様においては、上記量のセサミン類を、ヒトに経口で摂取させる又は投与することが好ましい。
一態様において、本発明の組成物は、ヒトに、体重６０ｋｇあたり、１日あたり上記量のセサミン類を摂取させる又は投与するために使用することができる。
上記総投与量は、セサミン類の化合物を２種以上使用する場合は、これらの合計量である。
一態様においては、セサミン及び／又はエピセサミンを、セサミン及びエピセサミンの総投与量として１日当たり体重６０ｋｇで、好ましくは０．５～２００ｍｇ、より好ましくは１～１００ｍｇ、さらに好ましくは３～８０ｍｇ、ヒト（成人）に経口で摂取させる又は投与することが好ましい。 In one embodiment, when the composition of the present invention is orally ingested or administered to a human (adult), the total dose of sesamin is 60 kg body weight per day, preferably 0.5 mg or more, more preferably. It is 1 mg or more, more preferably 3 mg or more, preferably 200 mg or less, more preferably 100 mg or less, still more preferably 80 mg or less.
In one embodiment, the total dose of sesamin is 60 kg body weight per day for humans (adults), preferably 0.5 to 200 mg, more preferably 1 to 100 mg, still more preferably 3 to 80 mg.
It is preferable to ingest or administer the above amount once or more a day, for example, once a day or several times (for example, 2 to 3 times).
In one aspect, it is preferred that the above amounts of sesamin be orally ingested or administered to humans.
In one aspect, the compositions of the present invention can be used to allow humans to ingest or administer the above amounts of sesamin per 60 kg of body weight per day.
The total dose is the total amount when two or more sesamin compounds are used.
In one embodiment, sesamin and / or episesamin is used as the total dose of sesamin and episesamin at a body weight of 60 kg per day, preferably 0.5 to 200 mg, more preferably 1 to 100 mg, still more preferably 3 to 80 mg, human ( It is preferable to ingest or administer it orally to an adult).
一態様において、セサミン類の総投与量は、ヒト（成人）であれば、１日当たり体重６０ｋｇで、好ましくは０．５～２００ｍｇ、より好ましくは１～１００ｍｇ、さらに好ましくは３～８０ｍｇである。
上記量を、１日１回以上、例えば、１日１回又は数回（例えば２～３回）に分けて、摂取させる又は投与することが好ましい。
一態様においては、上記量のセサミン類を、ヒトに経口で摂取させる又は投与することが好ましい。
一態様において、本発明の組成物は、ヒトに、体重６０ｋｇあたり、１日あたり上記量のセサミン類を摂取させる又は投与するために使用することができる。
上記総投与量は、セサミン類の化合物を２種以上使用する場合は、これらの合計量である。
一態様においては、セサミン及び／又はエピセサミンを、セサミン及びエピセサミンの総投与量として１日当たり体重６０ｋｇで、好ましくは０．５～２００ｍｇ、より好ましくは１～１００ｍｇ、さらに好ましくは３～８０ｍｇ、ヒト（成人）に経口で摂取させる又は投与することが好ましい。 In one embodiment, when the composition of the present invention is orally ingested or administered to a human (adult), the total dose of sesamin is 60 kg body weight per day, preferably 0.5 mg or more, more preferably. It is 1 mg or more, more preferably 3 mg or more, preferably 200 mg or less, more preferably 100 mg or less, still more preferably 80 mg or less.
In one embodiment, the total dose of sesamin is 60 kg body weight per day for humans (adults), preferably 0.5 to 200 mg, more preferably 1 to 100 mg, still more preferably 3 to 80 mg.
It is preferable to ingest or administer the above amount once or more a day, for example, once a day or several times (for example, 2 to 3 times).
In one aspect, it is preferred that the above amounts of sesamin be orally ingested or administered to humans.
In one aspect, the compositions of the present invention can be used to allow humans to ingest or administer the above amounts of sesamin per 60 kg of body weight per day.
The total dose is the total amount when two or more sesamin compounds are used.
In one embodiment, sesamin and / or episesamin is used as the total dose of sesamin and episesamin at a body weight of 60 kg per day, preferably 0.5 to 200 mg, more preferably 1 to 100 mg, still more preferably 3 to 80 mg, human ( It is preferable to ingest or administer it orally to an adult).
本発明の組成物は、継続して摂取又は投与されるものであることが好ましい。セサミン類は、継続的に摂取又は投与されることによって、上記の効果が高まることが期待される。一態様において、本発明の組成物は、好ましくは１週間以上、より好ましくは４週間以上、さらに好ましくは８週間以上継続して、特に好ましくは１２週間以上継続して摂取又は投与されることが好ましい。
The composition of the present invention is preferably continuously ingested or administered. It is expected that the above effects will be enhanced by continuously ingesting or administering sesamin. In one embodiment, the composition of the present invention is preferably ingested or administered continuously for 1 week or longer, more preferably 4 weeks or longer, further preferably 8 weeks or longer, and particularly preferably 12 weeks or longer. preferable.
本発明の組成物を摂取させる又は投与する対象（投与対象ということもできる）は、特に限定されず、ヒト及びヒト以外の動物に摂取させることができる。ヒト以外の動物としては、例えば、産業動物、ペットおよび実験動物等が挙げられる。具体的に、産業動物とは、ウシ、ウマ、ブタ、ヤギ及びヒツジ等の家畜、ニワトリ、アヒル、ウズラ、七面鳥及びダチョウ等の家禽、並びに、ブリ、ハマチ、マダイ、マアジ、コイ、ニジマス及びウナギ等の魚類等、産業上飼養することが必要とされている動物をいう。ペットとはイヌ、ネコ、マーモセット、小鳥及びハムスター等のいわゆる愛玩動物、コンパニオン・アニマルをいい、実験動物とはマウス、ラット、モルモット、ビーグル犬、ミニブタ、アカゲザル及びカニクイザル等、医学、生物学、農学及び薬学等の分野で研究に供用される動物を表す。
The subject to ingest or administer the composition of the present invention (which may also be the subject of administration) is not particularly limited, and can be ingested by humans and non-human animals. Examples of non-human animals include industrial animals, pets, laboratory animals and the like. Specifically, industrial animals include livestock such as cattle, horses, pigs, goats and sheep, poultry such as chickens, ducks, quail, turkeys and ostriches, as well as yellowtail, hamachi, madai, maji, koi, nigga and eel. This refers to animals that are industrially required to be bred, such as fish such as yellowtail. Pets are so-called companion animals such as dogs, cats, marmosets, small birds and hamsters, and companion animals. And represents animals used for research in fields such as pharmacy.
本発明の組成物の投与対象は、好ましくはヒト又は非ヒト哺乳動物であり、より好ましくはヒトである。
一態様において、投与対象として、生活活動量の維持、低下予防、低下抑制又は改善を必要とする又は希望する対象が挙げられる。このような対象として、例えば、中高年の者、生活活動量及び／又は生活活動時間の維持、低下予防、低下抑制又は改善を必要とする又は希望する対象、生活活動を行う活力又は気力の低下を感じている対象等が挙げられる。中高年の者は、例えば、４０歳以上のヒトであってよい。中高齢者は、高齢者を含む概念である。一態様において中高年者の中でも、対象として高齢者が好ましい。高齢者は、例えば、６０歳以上又は６５歳以上のヒトであってよい。本発明の組成物は、例えば、生活活動量及び／又は生活活動時間の維持、低下予防、低下抑制又は改善により予防又は改善が期待できる症状又は疾患の予防等を目的として、健常者に対して使用することもできる。 The administration target of the composition of the present invention is preferably a human or a non-human mammal, and more preferably a human.
In one aspect, the administration target includes a subject who needs or desires to maintain, prevent a decrease in the amount of daily activity, suppress or suppress the decrease, or abide. Such targets include, for example, middle-aged and elderly people, subjects who need or desire to maintain, prevent decline, suppress decline or improve living activity amount and / or daily activity time, and decrease vitality or energy to perform daily activities. There are objects that you feel. The middle-aged person may be, for example, a person aged 40 years or older. Middle-aged and elderly people are a concept that includes elderly people. Among the middle-aged and elderly people in one aspect, the elderly are preferable as the target. The elderly person may be, for example, a person aged 60 years or older or a person aged 65 years or older. The composition of the present invention is used, for example, for a healthy person for the purpose of maintaining, preventing, suppressing or improving the amount of daily activity and / or the time of daily living, for the purpose of preventing or preventing a symptom or disease that can be expected to be prevented or improved. It can also be used.
一態様において、投与対象として、生活活動量の維持、低下予防、低下抑制又は改善を必要とする又は希望する対象が挙げられる。このような対象として、例えば、中高年の者、生活活動量及び／又は生活活動時間の維持、低下予防、低下抑制又は改善を必要とする又は希望する対象、生活活動を行う活力又は気力の低下を感じている対象等が挙げられる。中高年の者は、例えば、４０歳以上のヒトであってよい。中高齢者は、高齢者を含む概念である。一態様において中高年者の中でも、対象として高齢者が好ましい。高齢者は、例えば、６０歳以上又は６５歳以上のヒトであってよい。本発明の組成物は、例えば、生活活動量及び／又は生活活動時間の維持、低下予防、低下抑制又は改善により予防又は改善が期待できる症状又は疾患の予防等を目的として、健常者に対して使用することもできる。 The administration target of the composition of the present invention is preferably a human or a non-human mammal, and more preferably a human.
In one aspect, the administration target includes a subject who needs or desires to maintain, prevent a decrease in the amount of daily activity, suppress or suppress the decrease, or abide. Such targets include, for example, middle-aged and elderly people, subjects who need or desire to maintain, prevent decline, suppress decline or improve living activity amount and / or daily activity time, and decrease vitality or energy to perform daily activities. There are objects that you feel. The middle-aged person may be, for example, a person aged 40 years or older. Middle-aged and elderly people are a concept that includes elderly people. Among the middle-aged and elderly people in one aspect, the elderly are preferable as the target. The elderly person may be, for example, a person aged 60 years or older or a person aged 65 years or older. The composition of the present invention is used, for example, for a healthy person for the purpose of maintaining, preventing, suppressing or improving the amount of daily activity and / or the time of daily living, for the purpose of preventing or preventing a symptom or disease that can be expected to be prevented or improved. It can also be used.
本発明の組成物には、生活活動量及び／又は生活活動時間の維持、低下予防、低下抑制又は改善により発揮される機能の表示が付されていてもよい。このような表示として、例えば、「加齢とともに低下する生活活動量を維持又は向上させる」、「加齢とともに低下する生活活動時間を維持又は延長する」、「加齢とともに増加する不活動時間の増加を抑制、予防、短縮又は改善する」、「日常生活における歩行などの生活活動量を維持または向上させる」、「趣味やレジャー、仕事上の活動などの生活活動量を維持または向上させる」、「活動的な生活をサポートする」、「日常生活動作能力の低下抑制、低下予防、維持、改善又は向上」、及び、「自立した生活活動の維持」からなる群から選択される１又は２以上の機能の表示が付されていてもよい。
本発明の一態様において、本発明の組成物は、上記の表示が付された飲食品であることが好ましい。また上記の表示は、上記の機能を得るために用いる旨の表示であってもよい。 The composition of the present invention may be labeled with a function exerted by maintaining, preventing, suppressing or improving the amount of daily activity and / or the time of daily living. Such indications include, for example, "maintaining or improving the amount of daily activity that decreases with age", "maintaining or extending the time of daily living that decreases with age", and "maintaining or extending the amount of inactivity that increases with age". "Suppress, prevent, shorten or improve", "Maintain or improve activities of daily living such as walking", "Maintain or improve activities of daily living such as hobbies, leisure and work activities", One or more selected from the group consisting of "supporting active life", "suppressing, preventing, maintaining, improving or improving activities of daily living", and "maintaining independent living activities" Function display may be attached.
In one aspect of the present invention, the composition of the present invention is preferably a food or drink with the above indication. Further, the above display may be a display to the effect that it is used to obtain the above function.
本発明の一態様において、本発明の組成物は、上記の表示が付された飲食品であることが好ましい。また上記の表示は、上記の機能を得るために用いる旨の表示であってもよい。 The composition of the present invention may be labeled with a function exerted by maintaining, preventing, suppressing or improving the amount of daily activity and / or the time of daily living. Such indications include, for example, "maintaining or improving the amount of daily activity that decreases with age", "maintaining or extending the time of daily living that decreases with age", and "maintaining or extending the amount of inactivity that increases with age". "Suppress, prevent, shorten or improve", "Maintain or improve activities of daily living such as walking", "Maintain or improve activities of daily living such as hobbies, leisure and work activities", One or more selected from the group consisting of "supporting active life", "suppressing, preventing, maintaining, improving or improving activities of daily living", and "maintaining independent living activities" Function display may be attached.
In one aspect of the present invention, the composition of the present invention is preferably a food or drink with the above indication. Further, the above display may be a display to the effect that it is used to obtain the above function.
本発明は、以下の方法も包含する。
セサミン類の１種以上を投与する、生活活動量及び／又は生活活動時間の維持、低下予防、低下抑制又は改善方法。 The present invention also includes the following methods.
A method for maintaining, preventing, suppressing or ameliorating a decrease in the amount of daily activity and / or a period of daily activity by administering one or more of sesamin.
セサミン類の１種以上を投与する、生活活動量及び／又は生活活動時間の維持、低下予防、低下抑制又は改善方法。 The present invention also includes the following methods.
A method for maintaining, preventing, suppressing or ameliorating a decrease in the amount of daily activity and / or a period of daily activity by administering one or more of sesamin.
本発明は、以下の使用も包含する。
生活活動量及び／又は生活活動時間の維持、低下予防、低下抑制又は改善のための、セサミン類の１種以上の使用。
上記方法及び使用は、治療的な方法又は使用であってもよく、非治療的な方法又は使用であってもよい。
セサミン類の１種以上を対象に投与することにより、生活活動量及び／又は生活活動時間の維持、低下予防、低下抑制又は改善が可能となる。 The present invention also includes the following uses.
Use of one or more sesamin for maintaining, preventing, suppressing or ameliorating the amount and / or time of daily living.
The methods and uses may be therapeutic or non-therapeutic methods or uses.
By administering one or more kinds of sesamin to a subject, it is possible to maintain, prevent, suppress or improve the amount of daily activity and / or the time of daily activity.
生活活動量及び／又は生活活動時間の維持、低下予防、低下抑制又は改善のための、セサミン類の１種以上の使用。
上記方法及び使用は、治療的な方法又は使用であってもよく、非治療的な方法又は使用であってもよい。
セサミン類の１種以上を対象に投与することにより、生活活動量及び／又は生活活動時間の維持、低下予防、低下抑制又は改善が可能となる。 The present invention also includes the following uses.
Use of one or more sesamin for maintaining, preventing, suppressing or ameliorating the amount and / or time of daily living.
The methods and uses may be therapeutic or non-therapeutic methods or uses.
By administering one or more kinds of sesamin to a subject, it is possible to maintain, prevent, suppress or improve the amount of daily activity and / or the time of daily activity.
上記の方法及び使用において、セサミン類及びその好ましい態様は、上述した本発明の組成物と同じである。セサミン類の１種以上として、セサミン類の化合物１種を使用してもよく、２種以上を使用してもよい。上記方法及び使用においては、１日に１回以上、例えば、１日１回～数回（例えば２～３回）、セサミン類の１種以上を対象に投与する（摂取させる）ことが好ましい。上記方法及び使用においては、セサミン類を、経口投与（摂取）することが好ましい。上記の使用は、好ましくはヒト又は非ヒト哺乳動物、より好ましくはヒトにおける使用である。
In the above methods and uses, sesamins and preferred embodiments thereof are the same as the compositions of the present invention described above. As one or more kinds of sesamin, one kind of compound of sesamin may be used, and two or more kinds may be used. In the above method and use, it is preferable to administer (ingest) one or more kinds of sesamin to the subject at least once a day, for example, once to several times a day (for example, 2 to 3 times). In the above method and use, it is preferable to orally administer (ingest) sesamin. The above use is preferably in humans or non-human mammals, more preferably in humans.
上記方法及び使用においては、所望の作用が得られる量（有効量ということもできる）のセサミン類の１種以上を使用すればよい。セサミン類の好ましい投与量や投与対象等は上述した本発明の組成物と同じである。セサミン類は、そのまま投与してもよく、これを含む組成物として投与してもよい。例えば、上述した本発明の組成物を使用してもよい。
In the above method and use, one or more kinds of sesamin in an amount (which can be said to be an effective amount) that can obtain a desired action may be used. The preferred dose of sesamin, the subject of administration, and the like are the same as those of the composition of the present invention described above. The sesamin may be administered as it is, or may be administered as a composition containing the sesamin. For example, the composition of the present invention described above may be used.
本発明は、本発明の組成物を製造するための、セサミン類の１種以上の使用も包含する。なお、本明細書中に記載された学術文献及び特許文献の全ては、参照として本明細書に組み入れられる。
The present invention also includes the use of one or more sesamins for producing the compositions of the present invention. All academic and patent documents described herein are incorporated herein by reference.
以下、本発明を実施例に基づいてより具体的に説明する。一連の動物実験は、動物愛護管理法他関連法令を遵守し、社内動物実験委員会の審査を経て機関の長が承認した計画に基づき実施した。なお、本発明はこれらの実施例に限定されるものではない。
Hereinafter, the present invention will be described in more detail based on examples. A series of animal experiments were conducted based on a plan approved by the head of the institution after being examined by the in-house animal experiment committee in compliance with the Act on Welfare and Management of Animals and other related laws and regulations. The present invention is not limited to these examples.
＜実施例１：セサミン・エピセサミン混合物（１：１）生活活動量低下抑制効果（ｉｎ ｖｉｖｏ試験）＞
本実験では運動負荷をかけない条件で行うため、測定された活動量はすべてヒトでいう生活活動量に相当すると考えられる。通常飼料群とセサミン・エピセサミン含有飼料群は、生活活動量が均等になるように群を分けた。生活活動量の測定には、加速度計測器ｎａｎｏｔａｇ（キッセイコムテック株式会社製）を使用した。１４ヵ月齢のＳｌｃ：ＳＤ雄性ラットにイソフルラン麻酔下で、頸部皮下に加速度計測器を埋め込み、回復を確認した後、活動期（暗期）の活動量を３日間測定した。生活活動量の測定では、一定強度以上の振動の数を継続して計測し、振動数の合計を生活活動量とした。通常飼料（ＡＩＮ－９３Ｍ、日本クレア（株）製）又は通常飼料に０．１重量％セサミン及びエピセサミン混合物（セサミン：エピセサミン（重量比）＝１：１）を含有させた飼料（試験食）を摂取させる群に分け（各８匹／群）、それぞれの飼料（試験食）を８ヶ月間摂取させた。通常飼料を摂取させた群を老齢通常飼料群（通常飼料群）、０．１重量％セサミン及びエピセサミンを含有する飼料を摂取させた群を、老齢セサミン・エピセサミン含有飼料群（セサミン・エピセサミン含有飼料群）という。なおセサミン及びエピセサミンを含有する飼料は、セサミン及びエピセサミンの総含有量が０．１重量％であり、通常飼料にセサミン及びエピセサミン混合物（セサミン：エピセサミン（重量比）＝１：１）を混合して調製された。
１７カ月齢、２２ヵ月齢時点で活動期の生活活動量を１週間測定した。
動物の健康状態を把握するため、定期的に摂餌量と体重を測定し、試験継続が困難と判断したラットは、適切な安楽死処分を実施し、解析から除外した。最終的解析対象は、老齢通常飼料群４匹、老齢セサミン・エピセサミン含有飼料群６匹となった。 <Example 1: Sesamin / episesamin mixture (1: 1) Effect of suppressing decrease in activities of daily living (in vivo test)>
Since this experiment is performed under the condition that no exercise load is applied, it is considered that all the measured activity amounts correspond to the daily activity amount in humans. The normal feed group and the sesamin / episesamin-containing feed group were divided into groups so that the amount of daily activities was equal. An acceleration measuring instrument nanotag (manufactured by Kissei Comtec Co., Ltd.) was used to measure the amount of daily activities. A 14-month-old Slc: SD male rat was anesthetized with isoflurane, and an accelerometer was implanted under the skin of the neck. After confirming recovery, the amount of activity during the active period (dark period) was measured for 3 days. In the measurement of the amount of daily activity, the number of vibrations above a certain intensity was continuously measured, and the total number of frequencies was taken as the amount of daily activity. A normal feed (AIN-93M, manufactured by Nippon Claire Co., Ltd.) or a feed (test meal) containing 0.1% by weight sesamin and a mixture of episesamin (sesamin: episesamin (weight ratio) = 1: 1). They were divided into groups to be ingested (8 animals / group each), and each feed (test meal) was ingested for 8 months. The group fed with the normal feed was the old-age normal feed group (normal feed group), and the group fed with the feed containing 0.1% by weight sesamin and episesamin was the old-age sesamin / episesamin-containing feed group (sesamin / episesamin-containing feed). Group). The feed containing sesamin and episesamin has a total content of sesamin and episesamin of 0.1% by weight, and a mixture of sesamin and episesamin (sesamin: episesamin (weight ratio) = 1: 1) is mixed with the normal feed. Prepared.
At the ages of 17 months and 22 months, the amount of daily activity during the active period was measured for one week.
Rats that were determined to be difficult to continue the study by regularly measuring food intake and body weight to understand the health of the animals were subjected to appropriate euthanasia and excluded from the analysis. The final analysis subjects were 4 animals in the old-age normal feed group and 6 animals in the old-age sesamin / episesamin-containing feed group.
本実験では運動負荷をかけない条件で行うため、測定された活動量はすべてヒトでいう生活活動量に相当すると考えられる。通常飼料群とセサミン・エピセサミン含有飼料群は、生活活動量が均等になるように群を分けた。生活活動量の測定には、加速度計測器ｎａｎｏｔａｇ（キッセイコムテック株式会社製）を使用した。１４ヵ月齢のＳｌｃ：ＳＤ雄性ラットにイソフルラン麻酔下で、頸部皮下に加速度計測器を埋め込み、回復を確認した後、活動期（暗期）の活動量を３日間測定した。生活活動量の測定では、一定強度以上の振動の数を継続して計測し、振動数の合計を生活活動量とした。通常飼料（ＡＩＮ－９３Ｍ、日本クレア（株）製）又は通常飼料に０．１重量％セサミン及びエピセサミン混合物（セサミン：エピセサミン（重量比）＝１：１）を含有させた飼料（試験食）を摂取させる群に分け（各８匹／群）、それぞれの飼料（試験食）を８ヶ月間摂取させた。通常飼料を摂取させた群を老齢通常飼料群（通常飼料群）、０．１重量％セサミン及びエピセサミンを含有する飼料を摂取させた群を、老齢セサミン・エピセサミン含有飼料群（セサミン・エピセサミン含有飼料群）という。なおセサミン及びエピセサミンを含有する飼料は、セサミン及びエピセサミンの総含有量が０．１重量％であり、通常飼料にセサミン及びエピセサミン混合物（セサミン：エピセサミン（重量比）＝１：１）を混合して調製された。
１７カ月齢、２２ヵ月齢時点で活動期の生活活動量を１週間測定した。
動物の健康状態を把握するため、定期的に摂餌量と体重を測定し、試験継続が困難と判断したラットは、適切な安楽死処分を実施し、解析から除外した。最終的解析対象は、老齢通常飼料群４匹、老齢セサミン・エピセサミン含有飼料群６匹となった。 <Example 1: Sesamin / episesamin mixture (1: 1) Effect of suppressing decrease in activities of daily living (in vivo test)>
Since this experiment is performed under the condition that no exercise load is applied, it is considered that all the measured activity amounts correspond to the daily activity amount in humans. The normal feed group and the sesamin / episesamin-containing feed group were divided into groups so that the amount of daily activities was equal. An acceleration measuring instrument nanotag (manufactured by Kissei Comtec Co., Ltd.) was used to measure the amount of daily activities. A 14-month-old Slc: SD male rat was anesthetized with isoflurane, and an accelerometer was implanted under the skin of the neck. After confirming recovery, the amount of activity during the active period (dark period) was measured for 3 days. In the measurement of the amount of daily activity, the number of vibrations above a certain intensity was continuously measured, and the total number of frequencies was taken as the amount of daily activity. A normal feed (AIN-93M, manufactured by Nippon Claire Co., Ltd.) or a feed (test meal) containing 0.1% by weight sesamin and a mixture of episesamin (sesamin: episesamin (weight ratio) = 1: 1). They were divided into groups to be ingested (8 animals / group each), and each feed (test meal) was ingested for 8 months. The group fed with the normal feed was the old-age normal feed group (normal feed group), and the group fed with the feed containing 0.1% by weight sesamin and episesamin was the old-age sesamin / episesamin-containing feed group (sesamin / episesamin-containing feed). Group). The feed containing sesamin and episesamin has a total content of sesamin and episesamin of 0.1% by weight, and a mixture of sesamin and episesamin (sesamin: episesamin (weight ratio) = 1: 1) is mixed with the normal feed. Prepared.
At the ages of 17 months and 22 months, the amount of daily activity during the active period was measured for one week.
Rats that were determined to be difficult to continue the study by regularly measuring food intake and body weight to understand the health of the animals were subjected to appropriate euthanasia and excluded from the analysis. The final analysis subjects were 4 animals in the old-age normal feed group and 6 animals in the old-age sesamin / episesamin-containing feed group.
図１に、試験食開始前の生活活動量を１としたときの相対生活活動量の変化を示す。図１のグラフにおいて、●は老齢通常飼料群、▲は老齢セサミン・エピセサミン含有飼料群である（＊：ｐ＜０．０５、老齢通常飼料群に対して、ｒｅｐｅａｔｅｄ ｍｅａｓｕｒｅｓ ｔｗｏ－ｗａｙ ＡＮＯＶＡ）。値が低くなるほど活動性が低下していることを示す。図１に示す通り、通常飼料群では、加齢に伴って生活活動量が低下していた。一方で、セサミン・エピセサミン含有飼料群は、加齢に伴う生活活動量の低下が抑制され、反復測定の解析を実施したところ、試験食と時間の間に交互作用が見られた（ｐ＝０．０１４）。２２ヵ月齢では通常飼料群に比べて、セサミン・エピセサミン含有飼料群の生活活動量が有意に高かった（Ｂｏｎｆｅｒｏｎｉの検定、ｐ＝０．０２３）。
FIG. 1 shows the change in the relative activity of daily living when the activity of daily living before the start of the test meal is 1. In the graph of FIG. 1, ● is an old-age normal feed group, and ▲ is an old-age sesamin / episesamin-containing feed group (*: p <0.05, repeated measures two-way ANOVA for the old-age normal feed group). The lower the value, the lower the activity. As shown in FIG. 1, in the normal feed group, the amount of daily activity decreased with aging. On the other hand, in the sesamin / episesamin-containing diet group, the decrease in the amount of daily activity with aging was suppressed, and when repeated measurement analysis was performed, an interaction was observed between the test meal and time (p = 0). .014). At 22 months of age, the amount of daily activity in the sesamin / episesamin-containing diet group was significantly higher than that in the normal diet group (Bonferoni's test, p = 0.023).
＜実施例２：セサミン又はエピセサミン単独投与による生活活動量低下抑制効果（ｉｎ ｖｉｖｏ試験）＞
実施例２は、セサミン又はエピセサミンのどちらがより生活活動量低下抑制に寄与しているか検討するための試験である。基本的操作は、実施例１にしたがって実施した。
１４ヵ月齢のＳｌｃ：ＳＤ雄性ラットを活動量が均等になるように、通常飼料（ＣＥ―２、日本クレア（株）社製）、又は、０．１％セサミン若しくはエピセサミン含有飼料を摂取させる群に分け（３匹／群）、それぞれの飼料（試験食）を１ヶ月間摂取させた。試験食摂取１か月後の１６ヵ月齢の時点で活動期の生活活動量を測定した。最終的解析対象は、通常飼料群２匹、セサミン含有飼料群及びエピセサミン含有飼料群は各３匹となった。
表１に、試験食開始前の生活活動量を１としたときの、試験食摂取１カ月後の各群の生活活動量を示す。値が低くなるほど生活活動量が低下していることを示す。表１に示す通り、通常飼料群では、生活活動量が低下していた。一方で、セサミン含有飼料群及びエピセサミン含有飼料群では、通常飼料群に比べて、加齢による生活活動量の低下が抑制された。エピセサミン含有飼料群では、加齢による生活活動量の低下が認められなかった。 <Example 2: Sesamin or episesamin alone administration has an effect of suppressing a decrease in activities of daily living (in vivo test)>
Example 2 is a test for examining whether sesamin or episesamin contributes more to the suppression of decrease in activities of daily living. The basic operation was carried out according to Example 1.
A group in which 14-month-old Slc: SD male rats were fed a normal diet (CE-2, manufactured by Nippon Claire Co., Ltd.) or a diet containing 0.1% sesamin or episesamin so that the amount of activity was equal. The animals were divided into groups (3 animals / group), and each feed (test meal) was ingested for 1 month. At the age of 16 months, one month after ingesting the test meal, the amount of daily activity during the active period was measured. The final analysis targets were 2 animals in the normal feed group, 3 animals in each of the sesamin-containing feed group and the episesamin-containing feed group.
Table 1 shows the amount of daily activity of each group one month after ingestion of the test meal, assuming that the amount of daily activity before the start of the test meal is 1. The lower the value, the lower the amount of daily activity. As shown in Table 1, the amount of daily activity decreased in the normal feed group. On the other hand, in the sesamin-containing feed group and the episesamin-containing feed group, the decrease in the amount of daily activity due to aging was suppressed as compared with the normal feed group. In the episesamine-containing diet group, no decrease in daily activity due to aging was observed.
実施例２は、セサミン又はエピセサミンのどちらがより生活活動量低下抑制に寄与しているか検討するための試験である。基本的操作は、実施例１にしたがって実施した。
１４ヵ月齢のＳｌｃ：ＳＤ雄性ラットを活動量が均等になるように、通常飼料（ＣＥ―２、日本クレア（株）社製）、又は、０．１％セサミン若しくはエピセサミン含有飼料を摂取させる群に分け（３匹／群）、それぞれの飼料（試験食）を１ヶ月間摂取させた。試験食摂取１か月後の１６ヵ月齢の時点で活動期の生活活動量を測定した。最終的解析対象は、通常飼料群２匹、セサミン含有飼料群及びエピセサミン含有飼料群は各３匹となった。
表１に、試験食開始前の生活活動量を１としたときの、試験食摂取１カ月後の各群の生活活動量を示す。値が低くなるほど生活活動量が低下していることを示す。表１に示す通り、通常飼料群では、生活活動量が低下していた。一方で、セサミン含有飼料群及びエピセサミン含有飼料群では、通常飼料群に比べて、加齢による生活活動量の低下が抑制された。エピセサミン含有飼料群では、加齢による生活活動量の低下が認められなかった。 <Example 2: Sesamin or episesamin alone administration has an effect of suppressing a decrease in activities of daily living (in vivo test)>
Example 2 is a test for examining whether sesamin or episesamin contributes more to the suppression of decrease in activities of daily living. The basic operation was carried out according to Example 1.
A group in which 14-month-old Slc: SD male rats were fed a normal diet (CE-2, manufactured by Nippon Claire Co., Ltd.) or a diet containing 0.1% sesamin or episesamin so that the amount of activity was equal. The animals were divided into groups (3 animals / group), and each feed (test meal) was ingested for 1 month. At the age of 16 months, one month after ingesting the test meal, the amount of daily activity during the active period was measured. The final analysis targets were 2 animals in the normal feed group, 3 animals in each of the sesamin-containing feed group and the episesamin-containing feed group.
Table 1 shows the amount of daily activity of each group one month after ingestion of the test meal, assuming that the amount of daily activity before the start of the test meal is 1. The lower the value, the lower the amount of daily activity. As shown in Table 1, the amount of daily activity decreased in the normal feed group. On the other hand, in the sesamin-containing feed group and the episesamin-containing feed group, the decrease in the amount of daily activity due to aging was suppressed as compared with the normal feed group. In the episesamine-containing diet group, no decrease in daily activity due to aging was observed.
以上のことからセサミン及びエピセサミンは、加齢による生活活動量の低下を抑制し、生活活動量を維持、低下予防、低下抑制又は改善したことが示唆された。また、その作用はエピセサミンでより強いことが明らかとなった。
From the above, it was suggested that sesamin and episesamin suppressed the decrease in the amount of daily activity due to aging, and maintained, prevented the decrease, suppressed or improved the amount of daily activity. It was also revealed that the effect was stronger with episesamine.
From the above, it was suggested that sesamin and episesamin suppressed the decrease in the amount of daily activity due to aging, and maintained, prevented the decrease, suppressed or improved the amount of daily activity. It was also revealed that the effect was stronger with episesamine.
Claims (9)
- セサミン類の１種以上を含む生活活動量の維持、低下予防、低下抑制又は改善用組成物。 A composition for maintaining, preventing, suppressing or improving the amount of daily activity containing one or more sesamin.
- セサミン類の１種以上が、セサミン及び／又はエピセサミンである請求項１に記載の組成物。 The composition according to claim 1, wherein one or more of the sesamin are sesamin and / or episesamin.
- セサミン類の１種以上が、エピセサミンである請求項１又は２に記載の組成物。 The composition according to claim 1 or 2, wherein one or more of the sesamin are episesamin.
- 加齢に伴う生活活動量低下の予防若しくは抑制、加齢に伴い低下した生活活動量の改善、加齢に伴う不活動時間増加の予防若しくは抑制、加齢に伴い増加した不活動時間の改善のための請求項１～３のいずれか一項に記載の組成物。 Prevention or suppression of age-related decrease in daily activity, improvement of age-related decrease in daily activity, prevention or suppression of age-related increase in inactivity time, improvement of age-related increase in inactivity time The composition according to any one of claims 1 to 3.
- 経口用組成物である請求項１～４のいずれか一項に記載の組成物。 The composition according to any one of claims 1 to 4, which is an oral composition.
- 前記経口用組成物が飲食品、医薬品、医薬部外品又は飼料である請求項５に記載の組成物。 The composition according to claim 5, wherein the oral composition is a food or drink, a pharmaceutical product, a quasi drug, or a feed.
- 前記飲食品が特定保健用食品、栄養機能食品又は機能性表示食品である請求項６に記載の組成物。 The composition according to claim 6, wherein the food or drink is a food for specified health use, a nutritionally functional food, or a food with functional claims.
- セサミン類の１種以上を投与する、生活活動量の維持、低下予防、低下抑制又は改善方法。 A method for maintaining, preventing, suppressing or ameliorating a decrease in daily activity by administering one or more of sesamin.
- 生活活動量の維持、低下予防、低下抑制又は改善のための、セサミン類の１種以上の使用。
Use of one or more sesamin for maintaining, preventing, suppressing or ameliorating the amount of daily activity.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021551148A JPWO2021065664A1 (en) | 2019-10-04 | 2020-09-24 | |
| CN202080069358.3A CN114514022A (en) | 2019-10-04 | 2020-09-24 | Composition for maintaining living activity, preventing reduction, inhibiting or improving reduction thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019183905 | 2019-10-04 | ||
| JP2019-183905 | 2019-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021065664A1 true WO2021065664A1 (en) | 2021-04-08 |
Family
ID=75337310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2020/035986 WO2021065664A1 (en) | 2019-10-04 | 2020-09-24 | Composition for maintaining or improving daily life activity amount, or for preventing or suppressing decrease in daily life activity amount. |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPWO2021065664A1 (en) |
| CN (1) | CN114514022A (en) |
| TW (1) | TW202123954A (en) |
| WO (1) | WO2021065664A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015096072A (en) * | 2014-12-09 | 2015-05-21 | 国立大学法人北海道大学 | Physical activity promotor |
| JP2018141014A (en) * | 2007-03-15 | 2018-09-13 | サントリーホールディングス株式会社 | Anti-fatigue agent |
| JP2019001798A (en) * | 2015-08-07 | 2019-01-10 | 国立大学法人 筑波大学 | Activity motivation improver |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4995567B2 (en) * | 2004-12-28 | 2012-08-08 | サントリーホールディングス株式会社 | Sesamin / episesamin composition |
| KR101528380B1 (en) * | 2007-09-19 | 2015-06-11 | 산토리 홀딩스 가부시키가이샤 | Composition comprising sesamin component and arachidonic acid component |
| JP5280029B2 (en) * | 2007-09-19 | 2013-09-04 | サントリーホールディングス株式会社 | Composition containing sesamin and γ-oryzanol |
| WO2009038089A1 (en) * | 2007-09-19 | 2009-03-26 | Suntory Holdings Limited | Anti-fatigue agent comprising sesamin and vitamin-e |
| SG10201510301UA (en) * | 2007-09-19 | 2016-01-28 | Suntory Holdings Ltd | Compositions incorporating sesamin-class compounds and vitamin b1 class compounds |
| JP2015096494A (en) * | 2013-10-07 | 2015-05-21 | かどや製油株式会社 | In vivo redox status-improving agent |
| CN107405329B (en) * | 2015-03-23 | 2021-04-09 | 三得利控股株式会社 | Composition for improving circadian rhythm |
-
2020
- 2020-09-24 CN CN202080069358.3A patent/CN114514022A/en active Pending
- 2020-09-24 JP JP2021551148A patent/JPWO2021065664A1/ja active Pending
- 2020-09-24 WO PCT/JP2020/035986 patent/WO2021065664A1/en active Application Filing
- 2020-09-29 TW TW109133795A patent/TW202123954A/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018141014A (en) * | 2007-03-15 | 2018-09-13 | サントリーホールディングス株式会社 | Anti-fatigue agent |
| JP2015096072A (en) * | 2014-12-09 | 2015-05-21 | 国立大学法人北海道大学 | Physical activity promotor |
| JP2019001798A (en) * | 2015-08-07 | 2019-01-10 | 国立大学法人 筑波大学 | Activity motivation improver |
Non-Patent Citations (4)
| Title |
|---|
| "DHC Bannon Enzed Black Cesamine + Stamina 30 Day Supply", AMAZON, 17 June 2019 (2019-06-17), pages 1 - 4, XP055813273, Retrieved from the Internet <URL:https://www.amazon.co.jp/DHC-32182-/product-reviews/B01MSSW5SI> [retrieved on 20201027] * |
| "Gomasesamin", KADOYA.COM, 5 November 2016 (2016-11-05), pages 1 - 8, XP055813271, Retrieved from the Internet <URL:https://shop.kadoya.com/shop/pages/a_gomasesamin_se09.html?ad_code=13437> [retrieved on 20201027] * |
| "Lipid metabolism regulatory function of sesamin isomer", NARO, 2001, pages 1 - 3, XP055813329, Retrieved from the Internet <URL:https://www.naro.affrc.go.jp/project/results/laboratory/nfri/2001/nfri01-07.html> [retrieved on 20201105] * |
| 26 June 2017 (2017-06-26), pages 1 - 4, XP055813324, Retrieved from the Internet <URL:https://www.a-q-f.com/contents/extra/1704suntory/index.html> [retrieved on 20201027] * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202123954A (en) | 2021-07-01 |
| CN114514022A (en) | 2022-05-17 |
| JPWO2021065664A1 (en) | 2021-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1937232B1 (en) | Nutraceutical composition for the treatment of muscle wasting | |
| CA2680751C (en) | Use of dioxabicyclo[3.3.0]octane derivatives as anti-fatigue agents | |
| JP6095549B2 (en) | Composition containing riboflavin and sesamin | |
| KR20100074190A (en) | Composition comprising sesamin component and vitamin b1 component | |
| EP3169170B1 (en) | Composition comprising cinnamaldehyde and zinc | |
| WO2021065664A1 (en) | Composition for maintaining or improving daily life activity amount, or for preventing or suppressing decrease in daily life activity amount. | |
| WO2021230146A1 (en) | Composition containing sesamin or like and nr and/or nmn | |
| WO2021230145A1 (en) | Nicotinamide adenine dinucleotide (nad) concentration increasing agent | |
| WO2021205975A1 (en) | Composition for suppressing cellular senescence, and method for suppressing cellular senescence | |
| US20090221693A1 (en) | Novel use of organic compounds | |
| US20090163579A1 (en) | Novel use of nutraceutical compositions | |
| WO2021065661A1 (en) | Composition for suppression of decrease in muscle mass, prevention of decrease therein, maintenance thereof, recovery thereof or increase therein | |
| WO2022071117A1 (en) | Antifatigue composition and composition for improving, suppressing reduction of, and maintaining energy production performance | |
| DK3119385T3 (en) | COMPOSITION COMPREHENSIVE CANNEL ALDE AND ZINC TO IMPROVE SINKING | |
| WO2022131063A1 (en) | Composition for improving muscle flexibility | |
| JP3831157B2 (en) | Stool odor improver | |
| WO2016167855A1 (en) | Combination of albuterol and caffeine as synergistic treatment for obesity or sarcopenia | |
| JP2004091475A (en) | Composition for preventing or improving free fatty acid-related hyperlipemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20870886 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2021551148 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20870886 Country of ref document: EP Kind code of ref document: A1 |